CA2390476C - Apparatus and method for abdomino-pelvic chemotherapy perfusion and lavage - Google Patents
Apparatus and method for abdomino-pelvic chemotherapy perfusion and lavage Download PDFInfo
- Publication number
- CA2390476C CA2390476C CA002390476A CA2390476A CA2390476C CA 2390476 C CA2390476 C CA 2390476C CA 002390476 A CA002390476 A CA 002390476A CA 2390476 A CA2390476 A CA 2390476A CA 2390476 C CA2390476 C CA 2390476C
- Authority
- CA
- Canada
- Prior art keywords
- abdomino
- containment vessel
- perfusion
- patient
- pelvic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000010412 perfusion Effects 0.000 title claims abstract description 95
- 238000002512 chemotherapy Methods 0.000 title claims description 51
- 238000000034 method Methods 0.000 title claims description 39
- 239000012530 fluid Substances 0.000 claims abstract description 88
- 210000003815 abdominal wall Anatomy 0.000 claims abstract description 29
- 238000004891 communication Methods 0.000 claims description 33
- 239000000443 aerosol Substances 0.000 claims description 32
- 239000000725 suspension Substances 0.000 claims description 20
- 230000002977 hyperthermial effect Effects 0.000 claims description 14
- 230000002262 irrigation Effects 0.000 claims description 9
- 238000003973 irrigation Methods 0.000 claims description 9
- 230000004888 barrier function Effects 0.000 claims description 8
- 244000052616 bacterial pathogen Species 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 5
- 230000003028 elevating effect Effects 0.000 claims description 4
- 238000007689 inspection Methods 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 230000035508 accumulation Effects 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 238000001804 debridement Methods 0.000 claims description 2
- 208000035346 Margins of Excision Diseases 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 25
- 230000003187 abdominal effect Effects 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 20
- 238000011282 treatment Methods 0.000 description 18
- 210000003200 peritoneal cavity Anatomy 0.000 description 17
- 210000000683 abdominal cavity Anatomy 0.000 description 16
- 210000001015 abdomen Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000012829 chemotherapy agent Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000011462 intraperitoneal chemotherapy Methods 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 206010058040 Abdominal sepsis Diseases 0.000 description 5
- 206010020843 Hyperthermia Diseases 0.000 description 5
- 230000036031 hyperthermia Effects 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 210000004197 pelvis Anatomy 0.000 description 4
- 206010034674 peritonitis Diseases 0.000 description 4
- 208000002847 Surgical Wound Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000000771 oncological effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 208000036209 Intraabdominal Infections Diseases 0.000 description 2
- 206010038111 Recurrent cancer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000011500 cytoreductive surgery Methods 0.000 description 2
- 201000010255 female reproductive organ cancer Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 208000010918 peritoneal neoplasm Diseases 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010059070 Pelvic sepsis Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229920004738 ULTEM® Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 231100001251 short-term toxicity Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0233—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs
- A61M3/0254—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped
- A61M3/0258—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped by means of electric pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H35/00—Baths for specific parts of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/30—Gas therapy for therapeutic treatment of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2218/00—Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2218/001—Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body having means for irrigation and/or aspiration of substances to and/or from the surgical site
- A61B2218/007—Aspiration
- A61B2218/008—Aspiration for smoke evacuation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
- A61F2007/0069—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit with return means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0095—Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H2201/105—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy with means for delivering media, e.g. drugs or cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2203/00—Additional characteristics concerning the patient
- A61H2203/04—Position of the patient
- A61H2203/0443—Position of the patient substantially horizontal
- A61H2203/0456—Supine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1017—Peritoneal cavity
Abstract
An abdomino-pelvic perfusion and lavage apparatus (20) to which skin surrounding an incision through an abdominal wall can be attached and suspended. Scaffolding (58) carried by the containment vessel (22) supports and elevates the skin to form a well above and extending into the abdomino-pelvic cavity. The containment vessel (22) has openings that are sealed around the patient's torso, a base sealed to a table (32) on which a patient is positioned, a removable cover (42), and a plurality of fluid ports (44) communicating through the containment vessel wall (28). A reservoir (92) provides perfusion fluid for delivery to the well by one of the fluid ports (44) and receives return fluid from fluid ports (46). A
heater (98) can be used to heat perfusion fluid. An air evacuation system (120) can be connected to the fluid port (48) to evacuate gasses from within the containment vessel (22). The apparatus (20) can be used for repeated access to the abdomino-pelvic space in patients.
heater (98) can be used to heat perfusion fluid. An air evacuation system (120) can be connected to the fluid port (48) to evacuate gasses from within the containment vessel (22). The apparatus (20) can be used for repeated access to the abdomino-pelvic space in patients.
Description
APPARATUS AND METHOD FOR
ABDOMINO-PELVIC CHEMOTHERAPY PERFUSION AND LAVAGE
FIELD OF THE INVENTION
This invention relates to surgical appliances and methods, and more particularly to an improved apparatus and method for perfusion and lavage of an abdomino-pelvic area both during and after surgery; and in particular when using cell-cycle specific chemotherapy drugs which require long-term contact with tissues in order to achieve their optimal effect. By allowing prolonged and repeated access to an abdominal cavity the apparatus can assist in the management of serious intra-abdominal infections.
Additionally, by permitting repeated access to the abdominal cavity, the apparatus is adapted for non-oncologic use in the treatment of intra-abdominal sepsis, peritonitis and pancreatitis.
BACKGROUND OF THE INVENTION
One of the mechanisms of the dissemination of gastrointestinal and gynecologic cancers is the intraperitoneal dissemination of the disease. Without special treatments all patients with peritoneal dissemination of cancer die; most patients die within one year. In an attempt to improve the control of intra-abdominal cancer, large doses of anti-cancer drugs can be injected directly into the peritoneal cavity. This therapy has shown beneficial effects in selected patients. Also other therapies in addition to intraperitoneal chemotherapy have been developed in an effort to better control the peritoneal dissemination of cancer.
It has been observed that hyperthermia seems to have a direct anti-cancer effect and synergy with some types of anti-cancer drugs, so that the toxicity for cancer cells is significantly increased at an elevated temperature. Examples of chemotherapy drugs which have been found effective in hyperthermic perfusion of the peritoneal cavity are cisplatin (CDDP) and mitomycin C (MMC). Accordingly, hyperthermic peritoneal lavage with a chemotherapy solution has been utilized to wash away free cancer cells in the peritoneal cavity by irrigation with a large volume of perfusate, to kill cancer cells by hyperthermia, and to kill cancer cells by the direct effects of chemotherapy. However, due to the inherent long and short term toxicity of chemotherapy solutions to operating room personnel, lavage with a chemotherapy solution can only be safely performed in a contained environment that prevents splashing, spillage and aerosol contaminants from escaping into the local atmosphere creating an environmental hazard to health care personnel.
Conventional techniques employing hyperthermic peritoneal lavage rely upon the use of a tube for infusion of heated fluid into the peritoneal cavity, and one or more drain tubes for removing the perfusate from the cavity. The lavage fluid can.
contain acid to lower pH, sugar to elevate glucose levels, antibiotics, chemotherapy (using single or multiple agents) and fibrinolytic agents, and can be exchanged to irrigate away cancer cells, fibrinous debris and other intra-abdominal contaminants.
The tubes can be inserted through small stab incisions formed in a wall of the abdomen and guided by the surgeon into a general anatomic site in which irrigation is desired, or the surgeon can make a larger incision and visually place the tubes for appropriate irrigation of the peritoneal cavity.
Direct manipulation of the tubes and of the patient's viscera during chemotherapy perfusion of the abdomino-pelvic cavity in order to guarantee uniform distribution is impossible with the conventional stab-incision technique due to the lack of access to the patient's abdomino-pelvic cavity which is afforded to the surgeon. Although direct manipulation of the tubes and viscera may be accomplished in circumstances where large incisions are employed, the inability of these conventional open abdomen techniques to contain and prevent spillage of inherently toxic lavage fluid and its aerosols thus presents a significant risk of contamination of the surgical environment with a resultant unacceptable risk of exposure of health care personnel to toxic substances.
Heated intraperitoneal chemotherapy is used to bring as much dose intensity to the affected abdominal and pelvic surfaces as is possible. Heat by itself has been shown to have a greater toxicity for cancerous cells than for normal tissues. Heat also increases the penetration of chemotherapy into tissues. As the tissues soften in response to the heat the elevated interstitial pressure of a tumor mass may decrease thereby allowing improved drug penetration. Furthermore, heat increases the cytotoxicity of selected chemotherapy agents. This synergism occurs only at the interface of heat and body tissue, at the peritoneal surface.
However, in conventional techniques the temperature of the lavage fluid is typically monitored on the inflow and outflow tubes but not throughout the peritoneal cavity, thereby reducing the accuracy of control over temperature and thus possibly increasing the danger of heat injury and reducing the effectiveness of the hyperthermic treatment.
The effectiveness of hyperthermic abdomino-pelvic perfusion using conventional techniques is further reduced because the heated chemotherapy solutions may not reach cancer cells between adherent surfaces in the deep areas of the peritoneum or mesenterium, and thus the perfusate incompletely eradicates cancer cells within the peritoneal cavity.
Moreover, assessment of the efficacy of treatments for peritoneal surface cancer by measuring the ascites volume or imaging a layer of cancer by computer tomography or ultra-sonography or the cytologic examination of ascites is remarkably ineffective in revealing residual or recurrent cancer in the peritoneal cavity.
Additionally, the inability to contain the environment within which conventional abdomino-pelvic perfusion is performed for an extended period of time further reduces its effectiveness because it limits or precludes the ability to use cell-cycle specific drugs such as 5-fluorouracil, which achieve their optimal effect through continuous long-term exposure of 5-10 days.
There are limited diagnostic methods available to establish the occurrence of peritoneal dissemination of cancer. In most patients, this pattern of dissemination is seen at the time of surgical removal of the primary gastrointestinal or ovarian 5 cancer. In a small proportion of patients, the peritoneal recurrence of cancer can be imaged by abdominal computerized tomography. In other patients, the rise in a tumor marker can lead to the diagnosis of peritoneal dissemination. In some situations, a second look operation (SLO) is the only reliable procedure to assess the disease state of the cancer patient.
The SLO was introduced into gastrointestinal and gynecologic surgery to provide an oncologist with a means for assessing the status of the disease approximately one year after the initial operation, before advanced disease has occurred and before the reactivation of symptoms. In gynecology, especially, SLO has been gradually approved as a useful means for assessing tumor response, removing recurrent cancer, and planning subsequent treatment in the follow-up of patients with ovarian cancer.
In order to overcome at least some of the shortcomings of prior techniques, while at the same time taking advantage of the beneficial effect of intraperitoneal chemotherapy and hyperthermia in cancer therapies, a method and apparatus for continuous hyperthermic peritoneal perfusion in combination with the administration of anti-cancer drugs having synergism with hyperthermia was developed, and disclosed, in Takashi Fujimura, et al., "Continuous Hyperthermic Peritoneal Perfusion for the Treatment of Peritoneal Dissemination in Gastric Cancers and Subsequent Second-Look Operation", Cancer 65:65-71, 1990.
Other similar methods and apparatuses are disclosed in Sugarbaker, U. S. Patent No. 5,336,171, and Sugarbaker, "Management of Peritoneal Surface Malignancy using Intraperitoneal Chemotherapy and Cytoreductive Surgery", The Ludann Company, November 1998. Neuman, et al., U. S. Patent No. 5,437,683, also discloses an apparatus for repeatedly opening and closing an abdominal incision for repeated lavage of the intra-abdominal cavity.
The apparatus developed by Fujimura, et al., comprises an acrylic cylinder with a flange at each end. One of the flanges is positioned inside the abdominal wall and the other is suspended from two right-angled bars fixed to an operating table.
The cylinder is open-ended and is fixed in the surgical wound made by the surgeon. It is large enough to permit the small intestine to float in the perfusate which is a heated chemotherapy solution infused into the peritoneal cavity. Tubes extend into the peritoneal cavity through the cylinder are used to introduce and remove perfusion fluid from the cavity.
Although the Fujimura, et al. apparatus solved some of the problems of prior art systems and techniques, it is intended for use only in an operating room environment while the perfusion procedure is being performed and consequently precludes use of chemotherapy agents which achieve their optimal effect through long-term contact with the tissues. It does not protect against seepage of chemotherapy solution between the acrylic cylinder and the skin. Additionally, no protection of operating room personnel from splashing, spillage or aerosols is provided.
The Sugarbaker apparatus disclosed in U. S. Patent No.
5,336,171 is adapted to be secured in a midline abdominal incision, and comprises an open-ended cylindrical wall having an upper end projecting above the abdominal wall and a base end with means for securing and sealing the apparatus to the skin surrounding the abdominal incision, in a water-tight manner, to form a well for containing the lavage fluid used to treat the surfaces of the abdomen and pelvis. Heated lavage fluid under pressure with anti-cancer drugs are added until the abdominal and pelvic cavities are completely filled with the fluid. Although this apparatus solved some of the additional problems of prior art systems and techniques, the seals joining the apparatus to the skin surrounding the surgical incision failed to safely secure the apparatus in place and thus presented a risk of spilling the lavage fluid with consequent exposure of personnel to the chemotherapy fluids and aerosols.
The Neumann apparatus disclosed in U. S. Patent No.
5,437,683 is likewise adapted to be secured in an abdominal incision and comprises a fabric of plate-like securing elements that can be detachably connected to the body tissue and has a closure that can be repeatedly opened and closed. This apparatus is an adaptation of a zipper technique which seeks to provide a convenient means for the repeated opening and closing of the surgical site. This apparatus, however, is not adapted to accommodate chemotherapy lavage and thus is inapplicable for continuous hyperthermic peritoneal perfusion in combination with the administration of anti-cancer drugs having synergism with hyperthermia.
The Sugarbaker method and apparatus disclosed in "Management of Peritoneal Surface Malignancy using Intraperitoneal Chemotherapy and Cytoreductive Surgery", involves heated intraoperative intraperitoneal chemotherapy by an open technique characteristic in that a running monofilament suture is used to secure the skin edges surrounding an abdominal incision to a self-retaining retractor. A tent-like plastic sheet is incorporated into the sutures to create an open space beneath.
A slit is made in the plastic cover to afford the surgeon's hands access to the abdomen and pelvis whereby the surgeon can manipulate the viscera during the perfusion with the result that all of the anatomic structures within the peritoneal cavity are exposed to heat and to chemotherapy. Although this latter method and apparatus further solved some of the problems of prior art systems and techniques, the self-retaining retractor and tent-like plastic sheet preclude the ability to selectively and repeatedly open and close access to the abdomino-pelvic cavity, and to reliably prevent spillage of perfusion fluid or infiltration of the fluid's aerosols into the surrounding operating room environment, and thereby also limit its safe use.
Thus, it too precludes post-operative lavage coupled with the administration of intraperitoneal chemotherapy agents which achieve their optimal effect through long-term contact with the tissues.
Accordingly, there is a need for an abdomino-pelvic perfusion and lavage apparatus which is supported by an operating room table or bed upon which a patient is lying and which is sealed to the patient's anterior skin surface. It must allow for simple and secure suspension of the skin surrounding an incisional wound made through the abdominal wall. It must supply couplings for quick and easy connection of inflow and outflow tubes and temperature monitors through the wall of the apparatus.
There is also a need that such an apparatus be capable of being left in place after the patient leaves the operating room so that continuous perfusion or repeated lavaging can be performed in an aseptic condition using cell-cycle specific chemotherapy agents which require long-term contact with the target tissues.
Similarly, it is desirable that such an apparatus facilitate periodic manipulation of abdominal and pelvic contents and treatment in a surgical intensive care unit (SICU) without necessitating a further operation or even requiring further use of the operating room except to suture the abdomen closed. It is also desirable that the apparatus be sealable so that chemotherapy can be performed without danger of exposure of operating room and SICU personnel to chemotherapy aerosols.
Moreover, a further desired feature would include openings for free access to the peritoneal cavity for both visual inspection and for the introduction of a surgeon's hands for manipulation of the viscera. It is also desirable that there be couplings for 5 quick and easy mounting of an air evacuation system which can evacuate the chemotherapy aerosols when the appliance is opened.
Furthermore, since chemotherapy not only directly destroys tumor cells but also eliminates viable platelets, neutrophils and monocytes from the peritoneal cavity; the ability of the abdomen 10 to resist infection is reduced. Thus, it is imperative that the apparatus be adapted to maintain a strict aseptic environment when administering chemotherapy, handling abdominal tubes and drains, and during manipulation of the viscera.
SUMMARY OF THE INVENTION
The present invention is directed to an improved abdomino-pelvic perfusion and lavage apparatus adapted for use both during and after surgery and to which skin surrounding an incision formed through an abdominal wall of a patient can be attached and suspended. More particularly, the invention relates to an abdomino-pelvic perfusion and lavage apparatus for intraperitoneal treatment of diseases disseminated through the peritoneal cavity, and especially in the hyperthermic treatment of the peritoneal dissemination of gastrointestinal, ovarian and other intra-abdominal cancers. The invention especially allows the use of heat, coupled with manipulation of the organs, in peritoneal perfusion procedures and more particularly is adapted to be left in place after the patient leaves the operating room so that repeated lavaging can be performed using cell-cycle specific chemotherapy agents which require long-term contact with the target tissues. Additionally, by permitting repeated access to the abdominal cavity, the apparatus is adapted for non-oncologic use in the treatment of intra-abdominal sepsis, peritonitis and pancreatitis.
In one preferred embodiment the invention comprises a containment vessel impermeable to water and air, having a wall having a base, wherein the wall has an upper end with a perimeter edge which defines an upper opening, a lower end with a perimeter edge which defines a base opening, a cranial end with a perimeter edge which defines an opening, and a caudal end with a perimeter edge which defines an opening. A plurality of fluid ports which are capable of providing hydraulic and pneumatic communication through the wall of the containment vessel are also provided.
The containment vessel is adapted to be carried by a table on which the patient is positioned.
A further aspect of the invention comprises a scaffolding that is carried by the containment vessel for supporting and elevating the skin surrounding the incision made through the abdominal wall of the patient whereby said elevated skin forms a well above, and extending into, an abdomino-pelvic cavity.
A further aspect of the invention comprises a fluid supply reservoir which serves as a source for the perfusion fluid; a first pump in hydraulic communication with the fluid supply reservoir and at least one fluid port for providing the perfusion fluid from the source to the containment vessel; a second pump in hydraulic communication with the fluid supply reservoir and at least one fluid port for returning the perfusion fluid from the containment vessel back to the source; a heater in thermal communication with a fluid containing means to heat the perfusion fluid to a temperature of about 30 C to about 50 C during use of the containment vessel in hyperthermic peritoneal perfusion;
at least one inflow tube in hydraulic communication with the fluid port receiving the perfusion fluid from the source for providing the perfusion fluid to the well formed in the patient's abdomino-pelvic cavity; at least one drain tube in hydraulic communication with the fluid port returning the perfusion fluid to the source and having a distal intake end extended into the well in the patient's abdomino-pelvic cavity for providing the perfusion fluid from the well; at least one temperature sensor positioned in proximity with the distal intake end of the drain tube and in communication with a thermostatic control in communication with the heater.
A further aspect of the invention comprises at least one removable cover capable of being secured and sealed over the upper opening of the containment vessel to enclose the well formed therein, thereby forming a barrier to aerosols so that chemotherapy agents can be used without exposing personnel to chemotherapy aerosols, and whereby the containment vessel may be left in place on a patient who may then be returned to an WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 intensive care unit for follow-up examinations, continuous perfusion and repeated lavaging without introducing bacterial pathogens and without necessitating use of the operating room.
A further aspect of the invention comprises an air evacuator connected in pneumatic communication with one or more fluid ports to form a low air pressure gradient across the upper opening and thereby evacuate aerosols and gases from within the interior space whenever one or more of the sealable covers is open and thereby minimizing the risk of exposure of surgical and SICU
personnel to the chemotherapy aerosols and gases.
A further aspect of the invention comprises a plurality of port-seals for sealing hydraulic and pneumatic communication through any unused fluid ports. A cranial opening seal is also provided to seal hydraulic and pneumatic communication through the cranial opening between the containment vessel and a torso of the patient and a caudal opening seal is likewise provided to seal hydraulic and pneumatic communication through the caudal opening between the containment vessel and a torso of the patient. A base seal is provided to seal hydraulic and pneumatic communication between the containment vessel and the table.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a top perspective view showing a containment vessel according to the present invention, in position over a patient on an operating table, with a cover removed to reveal an upper opening through which a scaffolding is visible and to which a skin edge surrounding an abdominal incision has been elevated and sutured.
Fig. 2 is a top perspective view of the containment vessel depicted in Fig. 1, with the cover secured in place to close the upper opening, and the scaffolding in place and extending through sealable openings communicating through a wall of the containment vessel.
Fig. 3 is a top plan view of the containment vessel as depicted in Fig. 2, with the cover removed, and showing the scaffolding in place and extending through sealable openings communicating the wall of the containment vessel.
Fig. 4 is a right side elevational view of the containment vessel as depicted in Fig. 2, with the cover and scaffolding in place, the left side elevational view being substantially the same.
Fig. 5 is a front elevational view of the containment vessel as depicted in Fig. 2, with the cover and scaffolding in place, the rear elevational view being substantially the same.
Fig. 6 is a sectional view taken through line 6-6 of Fig.
4.
Fig. 7 is a top perspective view of the containment vessel depicted in Fig. 1 wherein a left side of the containment vessel has been cut away to better reveal the skin edges surrounding the abdominal incision which are elevated and sutured to the scaffolding thereby forming a well.
Fig. 8 is a partially schematic top plan view of the containment vessel of Figs. 1 and 2 in use with the cover removed WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 and the accessory devices connected in operative relationship.
Fig. 9 is a top plan view of an alternative embodiment of the containment vessel of the present invention, with the cover 5 removed, and wherein the scaffolding is carried by an inner surface of the wall of the containment vessel.
Fig. 10 is a top plan view of a further alternative embodiment of the containment vessel of the present invention, with the cover removed, and wherein the scaffolding is carried 10 by the inner surface of the wall of the containment vessel and is integral thereto.
Fig. 11 is a sectional view taken through line 11-11 of Fig.
10.
Fig. 12 is a top plan view of an alternative embodiment of 15 the containment vessel of the present invention wherein the scaffolding is a support ring supported by a suspension carried by the inner surface of the wall of the containment vessel.
Fig. 13 is a sectional view taken through line 13-13 of Fig.
12.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention comprises an apparatus for perfusing or lavaging the abdomino-pelvic cavity during or after surgery.
More particularly, the invention is directed to an abdomino-pelvic perfusion/lavage apparatus for treatment of diseases disseminated through the peritoneal cavity, and especially in the hyperthermic treatment of the peritoneal dissemination of gastrointestinal, ovarian and other intra-abdominal cancers. The invention especially allows the use of heat, coupled with manipulation of the organs, in peritoneal perfusion procedures. Additionally, the apparatus and method of the present invention can be used in conjunction with cell-cycle specific drugs so that a lavage fluid can be maintained in the abdomino-pelvic cavity for up to 5-10 days postoperatively for long-term exposure so that the chemotherapy agents achieve their optimal effect.
Any lavage fluid employed in the prior art can be used with the apparatus and method of the present invention.
Additionally, in patients with disease states like peritonitis and pancreatitis, it can be expected that the patient need not return to the operating room on numerous occasions in order to ensure that no sepsis remained, as is utilized in the "zipper" technique or in a gauze packing technique. The patient can merely be transferred to an SICU setting with the apparatus in place where continuous perfusion, repeated gauze packing, repeated inspection or repeated lavage of the abdominal cavity can be performed. Only when the abdominal or pelvic sepsis has resolved is surgical repair of the abdominal incision in the operating room required. Multiple return visits to the operating room are to be avoided in this new approach.
The apparatus of the present invention is adapted to be supported by an operating table or other generally planar surface which also supports a patient and to elevate and secure skin around a midline abdominal incision. The apparatus comprises an open-ended containment vessel with means for supporting the skin edges surrounding the incision thereby forming a well for containing a perfusion/lavage fluid used to treat the surfaces of the patient's abdomen and pelvis. For gastrointestinal and gynecologic cancer patients, this includes a majority of sites at risk for local recurrence and peritoneal seeding. Heated perfusion fluid with anti-cancer drugs can be added until the well formed in the abdominal and pelvic cavities is completely filled with the chemotherapy solution.
In the preferred embodiment of the present invention the apparatus is adapted to be used with a cover securable over the upper end of the containment vessel to thereby confine chemotherapy aerosols and thereby maintain the operating room and postanesthesia care unit environments safe for personnel during the administration of chemotherapy. Additionally, the apparatus is also adapted to be used with its upper end open. The cover, when used, can include one or more additional smaller openings which permit the surgeon to have access to the abdominal cavity for additional functions such as: visual inspections, making incisions, further cytoreduction, excising structures, suturing, selective positioning of the inflow and outflow tubes and temperature sensing devices, and for manual manipulation of the intra-abdominal organs so that all fibrinous accumulations that can harbor cancer cells are disbursed. In cancer patients this also allows manual debridement of the narrow margins of the WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 excision, manipulation of all peritoneal crevices, and visual inspection of all bowel surfaces. Since chemotherapy not only directly destroys tumor cells but also eliminates viable platelets, neutrophils and monocytes from the peritoneal cavity the ability of the abdomen to resist infection is reduced.
Accordingly, the apparatus of the present invention is also adapted to maintain a strict aseptic environment.
Sealable ports along the wall of the containment vessel provide selective connection of inflow and outflow tubes for passage of the lavage fluid, and for temperature sensing devices extended into the abdominal cavity.
Further sealable ports along the wall of the containment vessel also provide for the selective connection of an air evacuation device and thus permit the evacuation of chemotherapy aerosols, from the interior space within the containment vessel, through the wall of the containment vessel whenever one of the access openings is open without imposing physical interference to the surgeon's access.
In a preferred embodiment the perfusion fluid is heated by use of a heater and circulated by a pair of peristaltic pumps such as found in a conventional heart-lung machine. A single inflow tube is used for supplying the perfusion fluid to the well in the abdominal cavity; and one, two, three or more drain tubes are used for draining the perfusion fluid from the abdominal cavity's well.
In one preferred embodiment one drain tube is placed beneath the patient's right hemidiaphragm, one beneath the left hemidiaphragm and the other in the pelvic cavity. If the chest cavity is entered through an incision in the diaphragm, a fourth drain tube, a chest tube, can also be used. The drain tubes should be moderately stiff, with multiple side openings, and a heat sensor should be associated with the distal end of each for monitoring the temperature of the perfusion fluid, in situ, throughout the procedure.
Sampling of the perfusion fluid drained from the abdominal cavity can be performed throughout the procedure so that the absorption of chemotherapy can be ascertained, and a geiger counter can be located over the abdomen so that any absorption from the abdomen into the systemic circulation can be estimated.
This is accomplished with the use of radioactive technetium, which may or may not be attached to various molecules such as albumin. A counter over the heart can also be used to enable the amount of absorption from the abdomino-pelvic cavity to be documented in an on-line manner. Simultaneous readings in the abdominal cavity and over the heart thus enable the absorption of chemotherapy to be estimated and a maximum systemic dosage of drug delivered with the surgical or post-operative event.
The containment vessel is preferably made of a lightweight, but strong, plastic material which is impervious to water and air, such as Ultem T ' made by General Electric Company, with an elliptical shape in transverse cross-section. It and other components of the apparatus can be made disposable if desired.
To facilitate disposal of the used containment vessel, it can be scored at intervals to define fracture lines. The containment vessel can be made in several different sizes to accommodate different size patients and different size abdominal incisions.
5 In the preferred embodiments of the present invention a scaffolding can be affixed to the containment vessel for supporting and elevating the skin edges surrounding an incision made through the abdominal wall of the patient whereby the elevated skin forms a well above, and extending into, an 10 abdomino-pelvic cavity. The skin edges surrounding the incision are elevated and connected to the scaffolding by sutures or other connecting means.
In a first alternative embodiment a series of rods are placed through sealable openings near the upper end of the 15 containment vessel. A second embodiment uses a series of rods carried by the inner surface of the wall of the containment vessel. A third embodiment uses a scaffolding formed integrally with the inner surface of the wall of the containment vessel.
A fourth embodiment utilizes a support ring which can be 20 elevated and hung from a suspension carried by the inner surface or the upper edge of the wall of the containment vessel. The support ring can be in the form of either an open loop or a closed loop. It can be connected to the skin edges surrounding the incision either wholly before being suspended from the suspension, wholly after being suspended from the suspension or partially before and partially after being suspended from the WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 suspension.
The present invention has particular application where use of cell-cycle specific chemotherapy agents is desirable. An initial irrigation with a fibrinolytic agent can be first performed with the cover removed and the abdominal well open to the atmosphere. During this initial procedure all debris, cancer cells and fibrinous material can be flushed from the peritoneal cavity. Following the initial irrigation, the cover can be placed on top of the containment vessel and all fibrinolytic phase fluid can be removed from the abdomino-pelvic cavity. An irrigation with a heated chemotherapy solution can then be conducted. In the preferred embodiment of the present invention if the chemotherapy agent includes a cell-cycle specific drug, the patient, with the apparatus of the present invention remaining in place, can be transferred to a SICU where a lavage procedure can be maintained for up to 5-10 days without the need to return to the operating room except to close the abdomen at the end of the chemotherapy treatment. By using the apparatus of the present invention, the surgeon is able to re-enter the abdominal cavity with a greatly reduced risk of exposure of operating room personnel to chemotherapy aerosols. During this time, the surgeon can also manually debride the narrow margins of the excision, manipulate the peritoneal crevices, and visually inspect all bowel surfaces. After the lavage procedure is finally completed the surgeon is then able to perform all reconstructive procedures, such as bowel anastomoses and closure of the surgical incision.
The abdomino-pelvic lavage apparatus of the present invention can have uses other than in oncology. For instance, it can be used for treatment of patients with intra-abdominal sepsis by irrigating the abdominal cavity with antibiotic and fibrinolytic agents. In this way, all of the infected fibrin can be removed from the abdominal cavity. By the repeated manipulation of the abdominal contents and repeated irrigation of the abdominal cavity, pathogens will be dislodged whereby bacterial counts can be brought down to an extremely low level.
The additional time that the lavage fluid is permitted to be present in the abdominal cavity by use of the invention can be of great value in eliminating sources of bacterial or fungus infection. With the removal of all contaminated fibrinous material, the patient can be expected to improve more quickly from surgery.
The foregoing aspects and many of the attendant advantages of the present invention will become more readily appreciated to those skilled in the art as the same becomes better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein like reference characters designate like parts throughout the several views.
Referring more specifically to the drawings, a first embodiment of the present invention of improved abdomino-pelvic chemotherapy perfusion and lavage apparatus 20 is indicated in WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 Fig. 1. In this embodiment of the invention a containment vessel 22 having a generally elliptical shape in transverse cross-section with a longitudinal axis 24, is made of a material, preferably plastic, impervious to air and water. An upper perimeter edge 26 of a wall 28 defines an upper opening 30 in containment vessel 22. Containment vessel 22 is adapted to be carried by a table 32 on which a patient 34 is positioned. An absorbent-material blanket 36, which has a moisture-resistant membrane on one side, is extended laterally beyond patient 34 and is disposed between the bottom of wall 28 and table 32. As so disposed, absorbent-material blanket 36 forms an air and watertight seal between the bottom of wall 28 of containment vessel 22 and table 32.
Referring now to Fig. 2, a lower perimeter edge 38 of wall 28 defines a lower opening 40 (visible in Figs 5 and 6) . One or more sealable covers 42 can be placed over upper opening 30 of containment vessel 22. A plurality of sealable inflow ports 44, a plurality of sealable outflow ports 46, and a plurality of sealable vacuum ports 48 are disposed at spaced locations around the circumference of wall 28 and communicate through wall 28.
In the particular embodiment shown, a plurality of sealable openings 50 are also disposed at spaced locations along the upper portion of wall 28 and also communicate through said wall 28.
As is seen in Fig. 3, wall 28 has an inner surface 52 and an outer surface 54. In the embodiment shown, a plurality of rods 56 is placed through the plurality of sealable openings 50 24 CA 02390476 2002-05-07 pCT/US00/30923 and as thus disposed said rods 56 form a scaffolding 58 disposed between the oppositely facing surfaces of inner surface 52 of wall 28.
Referring now to Figs. 4-6, in the preferred embodiment of the present invention containment vessel 22 has a cranial end 60 with an opening 62 defined by a generally semi-elliptical perimeter edge 64; and a caudal end 66 with an opening 68 defined by a generally semi-elliptical perimeter edge 70. A first seal 72, preferably made of a pliable membrane material which is impervious to water and air, is disposed along perimeter edge 64 of opening 62. A similar second seal 74 is disposed along perimeter edge 70 of opening 68.
Referring back to Fig. 1, cranial opening 62 and caudal opening 68 are of sufficient size such that when in use containment vessel 22 straddles patient 34 while patient 34 is disposed in lower opening 40 of containment vessel 22 and such that the bottom of wall 28 of containment vessel 22 is carried by table 32 while perimeter edge 64 and perimeter edge 70 are disposed at a proper height above and proximate to, but not in contact with, patient 34. Patient 34's upper torso 76 is disposed in cranial opening 62 and patient 34's lower torso 78 is disposed in caudal opening 68. As thus disposed, first seal 72 seals cranial opening 62 around upper torso 76 and thereby forms an air and watertight seal in cranial opening 62. Second seal 74 likewise seals caudal opening 68 around lower torso 78 and thereby an air and watertight seal in caudal opening 68.
WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 Referring now to Fig. 7, which is a cut-away view of Fig.
1 wherein a portion of wall 28 of containment vessel 22 has been cut away and removed so as to provide a view into containment vessel 22, scaffolding 58 is disposed superior to patient 34's 5 abdominal area 80 surrounding where an incision 82 has been made or is intended to be made. After incision 82 is made in patient 34's abdominal area 80, a running suture 84 is secured through skin edge 86 surrounding incision 82. As each suture 84 is secured to skin edge 86 said suture 84 and the skin edge 86 10 attached thereto are vertically displaced upwardly by a surgeon (not shown) and as thus vertically displaced are disposed and secured to scaffolding 58 which then supports skin edge 86 in a vertically superior position relative to patient 34. After all sutures 84 are completed, the displacement of skin edge 86 15 thereby forms a well 88 above and extending into abdomino-pelvic cavity 90.
Referring now to Fig. 8, perfusion fluid is provided from supply reservoir 92 through one or more of sealable inflow ports 44 communicating through wall 28 to well 88 formed in abdomino-20 pelvic cavity 90. Fluid is withdrawn from well 88 through one or more of sealable outflow ports 46 and returned to supply reservoir 92.
The perfusion fluid is pumped from supply reservoir 92 by first pump 94 connected in hydraulic communication with supply 25 reservoir 92 and one or more of sealable inflow ports 44. A
second pump 96 connected in hydraulic communication with one or WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 more of sealable outflow ports 46 and supply reservoir 92 returns the fluid to supply reservoir 92. During use of apparatus 20 in hyperthermic peritoneal perfusion, a heater 98 heats the fluid to a temperature of about 30 C to about 50 C and preferably about 40 C to about 50 C and ideally about 44 C to about 46 C
so as to maintain the temperature of the fluid in well 88 of abdomino-pelvic cavity 90 at about 42.5 C.
An inflow tube 100, which is connected in hydraulic communication with the at least one sealable inflow port 44 which is connected in hydraulic communication with supply reservoir 92 and first pump 94, delivers the fluid to well 88. At least one drain tube 102, which is connected in hydraulic communication with the at least one sealable outflow port 46 connected in hydraulic communication with supply reservoir 92 and second pump 96, withdraws the chemotherapy solution from well 88 through its distal intake end 104.
In the preferred embodiment shown in Fig. 8 there are three drain tubes 102 having distal intake ends 104 extended into well 88 and abdomino-pelvic cavity 90. Distal intake end 104 of a first drain tube 102 is disposed beneath a left hemidiaphragm 106 of patient 34, distal intake end 104 of a second drain tube 102 is disposed beneath a right hemidiaphragm 108 of patient 34, and distal intake end 104 of a third drain tube 102 is disposed in a pelvis 110 of patient 34. If the chest cavity 112 of the patient 34 is also opened, a fourth drain tube (not shown) , being a chest tube, can be disposed having its distal intake end (not WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 shown) in chest cavity 112.
One or more temperature sensors 114 are disposed in close proximity with the distal intake end 104 of each drain tube 102 to measure the temperature of the perfusion fluid within abdomino-pelvic cavity 90, said temperature sensors 114 communicating to a thermostatic control 116 connected to heater 98.
In use longitudinal axis 24 of containment vessel 22 is axially aligned with patient 34. As thus aligned, containment vessel 22 is placed over abdominal area 80 surrounding where incision 82 is to be made.
In use during chemotherapy one or more selectively removable and sealable covers 42 (as shown in Fig. 2) are disposed over upper opening 30 of containment vessel 22 thereby enclosing an interior space 118 (visible in Figs. 1 and 7) within containment vessel 22 and thus encasing well 88. As shown in Fig. 8, air evacuator 120 is connected in pneumatic communication with one or more of sealable vacuum ports 48 to form an air pressure gradient across the upper opening 30 and when activated thereby evacuates aerosols and gases 122 from within interior space 118 whenever one or more of sealable covers 42 is open thereby minimizing the risk of exposure of surgical and SICU personnel (not shown) to the chemotherapy aerosols and gases 122.
Any unused inflow ports 44, outflow ports 46, vacuum ports 48, and openings 50 can be sealed by conventional capping or plugging means thereby forming a barrier to the chemotherapy aerosols and gases 122 so that chemotherapy agents can be used without exposing personnel to the chemotherapy aerosols and gases 122. By leaving sealable covers 42 in place and sealing unused inflow ports 44, outflow ports 46, vacuum ports 48, and openings 50, containment vessel 22 can also maintain an aseptic environment and thus be left in place on patient 34 who may then be returned to a surgical intensive care unit for follow-up examination and treatment. Maintenance of intraperitoneal lavage, repeated inspection and repeated lavage procedures can thus be accomplished without necessitating return to the operating room.
In one preferred embodiment shown in Figs. 1-8, one sealable inflow port 44 and two sealable outflow ports 46 are disposed at cranial end 60 of containment vessel 22. Similarly, one sealable inflow port 44 and two sealable outflow ports 46 are disposed at caudal end 66 of containment vessel 22.
In an alternative embodiment shown in Fig. 9, a plurality of rods 124 are carried by supports 126 disposed on the inner surface 52 of wall 28 thereby forming an interior support scaffolding 128.
In another alternative embodiment shown in Figs. 10 and 11, an integral support scaffolding 130 is integrally formed with inner surface 52 of wall 28.
In yet another alternative embodiment shown in Figs. 12 and 13, a closed loop support ring 132, which in use defines the shape of an open end of well 88, is disposed and suspended from a suspension 134 carried by the inner surface 52 of wall 28. In a further alternative embodiment support ring 132 can be in the form of an open loop. In the embodiment shown, support ring 132 can be placed on patient 34's abdominal area 80 surrounding incision 82. Skin edge 86 surrounding incision 82 can be affixed by sutures 84 or other connecting means to support ring 132.
Support ring 132, together with skin edge 86 connected thereto, can then be vertically displaced upwardly by the surgeon (not shown) to a vertically superior position and suspended from suspension 134 thereby forming well 88 above and extending into abdomino-pelvic cavity 90.
In an alternative embodiment, support ring 132 can be suspended from suspension 134 prior to being connected to skin edge 86. In yet another alternative embodiment support ring 132 can be partially connected to skin edge 86 before being suspended from suspension 134 and partially connected to skin edge 86 after being suspended from suspension 134.
In yet another embodiment, suspension 134 can be carried by upper perimeter edge 26 of a wall 28.
The invention thus provides a simple and effective apparatus for continuous perfusion and repeated lavage procedures in the abdomino-pelvic cavity, and especially an apparatus which enables the surgeon free and repeated access to the abdomino-pelvic cavity during the perfusion/lavage process and which permits accurate monitoring and control of temperature within the abdomino-pelvic cavity during treatment, particularly during WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination of intra-abdominal cancers and other related clinical situations. Additionally, by permitting repeated access to the abdominal cavity, the apparatus is adapted for non-5 oncologic use in the management of serious intra-abdominal infections and treatment of intra-abdominal sepsis, peritonitis and pancreatitis.
Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in 10 the art will appreciate that various modifications, additions and substitutions are possible without departing from the scope and spirit of the invention as disclosed in the accompanying claims.
Additionally, although in the preferred embodiments the shape of the containment vessel and the edges of the cranial and caudal 15 openings are described as elliptical and semi-elliptical, respectively, those skilled in the art will appreciate that these shapes can also be circular, rectangular, or compound shapes.
ABDOMINO-PELVIC CHEMOTHERAPY PERFUSION AND LAVAGE
FIELD OF THE INVENTION
This invention relates to surgical appliances and methods, and more particularly to an improved apparatus and method for perfusion and lavage of an abdomino-pelvic area both during and after surgery; and in particular when using cell-cycle specific chemotherapy drugs which require long-term contact with tissues in order to achieve their optimal effect. By allowing prolonged and repeated access to an abdominal cavity the apparatus can assist in the management of serious intra-abdominal infections.
Additionally, by permitting repeated access to the abdominal cavity, the apparatus is adapted for non-oncologic use in the treatment of intra-abdominal sepsis, peritonitis and pancreatitis.
BACKGROUND OF THE INVENTION
One of the mechanisms of the dissemination of gastrointestinal and gynecologic cancers is the intraperitoneal dissemination of the disease. Without special treatments all patients with peritoneal dissemination of cancer die; most patients die within one year. In an attempt to improve the control of intra-abdominal cancer, large doses of anti-cancer drugs can be injected directly into the peritoneal cavity. This therapy has shown beneficial effects in selected patients. Also other therapies in addition to intraperitoneal chemotherapy have been developed in an effort to better control the peritoneal dissemination of cancer.
It has been observed that hyperthermia seems to have a direct anti-cancer effect and synergy with some types of anti-cancer drugs, so that the toxicity for cancer cells is significantly increased at an elevated temperature. Examples of chemotherapy drugs which have been found effective in hyperthermic perfusion of the peritoneal cavity are cisplatin (CDDP) and mitomycin C (MMC). Accordingly, hyperthermic peritoneal lavage with a chemotherapy solution has been utilized to wash away free cancer cells in the peritoneal cavity by irrigation with a large volume of perfusate, to kill cancer cells by hyperthermia, and to kill cancer cells by the direct effects of chemotherapy. However, due to the inherent long and short term toxicity of chemotherapy solutions to operating room personnel, lavage with a chemotherapy solution can only be safely performed in a contained environment that prevents splashing, spillage and aerosol contaminants from escaping into the local atmosphere creating an environmental hazard to health care personnel.
Conventional techniques employing hyperthermic peritoneal lavage rely upon the use of a tube for infusion of heated fluid into the peritoneal cavity, and one or more drain tubes for removing the perfusate from the cavity. The lavage fluid can.
contain acid to lower pH, sugar to elevate glucose levels, antibiotics, chemotherapy (using single or multiple agents) and fibrinolytic agents, and can be exchanged to irrigate away cancer cells, fibrinous debris and other intra-abdominal contaminants.
The tubes can be inserted through small stab incisions formed in a wall of the abdomen and guided by the surgeon into a general anatomic site in which irrigation is desired, or the surgeon can make a larger incision and visually place the tubes for appropriate irrigation of the peritoneal cavity.
Direct manipulation of the tubes and of the patient's viscera during chemotherapy perfusion of the abdomino-pelvic cavity in order to guarantee uniform distribution is impossible with the conventional stab-incision technique due to the lack of access to the patient's abdomino-pelvic cavity which is afforded to the surgeon. Although direct manipulation of the tubes and viscera may be accomplished in circumstances where large incisions are employed, the inability of these conventional open abdomen techniques to contain and prevent spillage of inherently toxic lavage fluid and its aerosols thus presents a significant risk of contamination of the surgical environment with a resultant unacceptable risk of exposure of health care personnel to toxic substances.
Heated intraperitoneal chemotherapy is used to bring as much dose intensity to the affected abdominal and pelvic surfaces as is possible. Heat by itself has been shown to have a greater toxicity for cancerous cells than for normal tissues. Heat also increases the penetration of chemotherapy into tissues. As the tissues soften in response to the heat the elevated interstitial pressure of a tumor mass may decrease thereby allowing improved drug penetration. Furthermore, heat increases the cytotoxicity of selected chemotherapy agents. This synergism occurs only at the interface of heat and body tissue, at the peritoneal surface.
However, in conventional techniques the temperature of the lavage fluid is typically monitored on the inflow and outflow tubes but not throughout the peritoneal cavity, thereby reducing the accuracy of control over temperature and thus possibly increasing the danger of heat injury and reducing the effectiveness of the hyperthermic treatment.
The effectiveness of hyperthermic abdomino-pelvic perfusion using conventional techniques is further reduced because the heated chemotherapy solutions may not reach cancer cells between adherent surfaces in the deep areas of the peritoneum or mesenterium, and thus the perfusate incompletely eradicates cancer cells within the peritoneal cavity.
Moreover, assessment of the efficacy of treatments for peritoneal surface cancer by measuring the ascites volume or imaging a layer of cancer by computer tomography or ultra-sonography or the cytologic examination of ascites is remarkably ineffective in revealing residual or recurrent cancer in the peritoneal cavity.
Additionally, the inability to contain the environment within which conventional abdomino-pelvic perfusion is performed for an extended period of time further reduces its effectiveness because it limits or precludes the ability to use cell-cycle specific drugs such as 5-fluorouracil, which achieve their optimal effect through continuous long-term exposure of 5-10 days.
There are limited diagnostic methods available to establish the occurrence of peritoneal dissemination of cancer. In most patients, this pattern of dissemination is seen at the time of surgical removal of the primary gastrointestinal or ovarian 5 cancer. In a small proportion of patients, the peritoneal recurrence of cancer can be imaged by abdominal computerized tomography. In other patients, the rise in a tumor marker can lead to the diagnosis of peritoneal dissemination. In some situations, a second look operation (SLO) is the only reliable procedure to assess the disease state of the cancer patient.
The SLO was introduced into gastrointestinal and gynecologic surgery to provide an oncologist with a means for assessing the status of the disease approximately one year after the initial operation, before advanced disease has occurred and before the reactivation of symptoms. In gynecology, especially, SLO has been gradually approved as a useful means for assessing tumor response, removing recurrent cancer, and planning subsequent treatment in the follow-up of patients with ovarian cancer.
In order to overcome at least some of the shortcomings of prior techniques, while at the same time taking advantage of the beneficial effect of intraperitoneal chemotherapy and hyperthermia in cancer therapies, a method and apparatus for continuous hyperthermic peritoneal perfusion in combination with the administration of anti-cancer drugs having synergism with hyperthermia was developed, and disclosed, in Takashi Fujimura, et al., "Continuous Hyperthermic Peritoneal Perfusion for the Treatment of Peritoneal Dissemination in Gastric Cancers and Subsequent Second-Look Operation", Cancer 65:65-71, 1990.
Other similar methods and apparatuses are disclosed in Sugarbaker, U. S. Patent No. 5,336,171, and Sugarbaker, "Management of Peritoneal Surface Malignancy using Intraperitoneal Chemotherapy and Cytoreductive Surgery", The Ludann Company, November 1998. Neuman, et al., U. S. Patent No. 5,437,683, also discloses an apparatus for repeatedly opening and closing an abdominal incision for repeated lavage of the intra-abdominal cavity.
The apparatus developed by Fujimura, et al., comprises an acrylic cylinder with a flange at each end. One of the flanges is positioned inside the abdominal wall and the other is suspended from two right-angled bars fixed to an operating table.
The cylinder is open-ended and is fixed in the surgical wound made by the surgeon. It is large enough to permit the small intestine to float in the perfusate which is a heated chemotherapy solution infused into the peritoneal cavity. Tubes extend into the peritoneal cavity through the cylinder are used to introduce and remove perfusion fluid from the cavity.
Although the Fujimura, et al. apparatus solved some of the problems of prior art systems and techniques, it is intended for use only in an operating room environment while the perfusion procedure is being performed and consequently precludes use of chemotherapy agents which achieve their optimal effect through long-term contact with the tissues. It does not protect against seepage of chemotherapy solution between the acrylic cylinder and the skin. Additionally, no protection of operating room personnel from splashing, spillage or aerosols is provided.
The Sugarbaker apparatus disclosed in U. S. Patent No.
5,336,171 is adapted to be secured in a midline abdominal incision, and comprises an open-ended cylindrical wall having an upper end projecting above the abdominal wall and a base end with means for securing and sealing the apparatus to the skin surrounding the abdominal incision, in a water-tight manner, to form a well for containing the lavage fluid used to treat the surfaces of the abdomen and pelvis. Heated lavage fluid under pressure with anti-cancer drugs are added until the abdominal and pelvic cavities are completely filled with the fluid. Although this apparatus solved some of the additional problems of prior art systems and techniques, the seals joining the apparatus to the skin surrounding the surgical incision failed to safely secure the apparatus in place and thus presented a risk of spilling the lavage fluid with consequent exposure of personnel to the chemotherapy fluids and aerosols.
The Neumann apparatus disclosed in U. S. Patent No.
5,437,683 is likewise adapted to be secured in an abdominal incision and comprises a fabric of plate-like securing elements that can be detachably connected to the body tissue and has a closure that can be repeatedly opened and closed. This apparatus is an adaptation of a zipper technique which seeks to provide a convenient means for the repeated opening and closing of the surgical site. This apparatus, however, is not adapted to accommodate chemotherapy lavage and thus is inapplicable for continuous hyperthermic peritoneal perfusion in combination with the administration of anti-cancer drugs having synergism with hyperthermia.
The Sugarbaker method and apparatus disclosed in "Management of Peritoneal Surface Malignancy using Intraperitoneal Chemotherapy and Cytoreductive Surgery", involves heated intraoperative intraperitoneal chemotherapy by an open technique characteristic in that a running monofilament suture is used to secure the skin edges surrounding an abdominal incision to a self-retaining retractor. A tent-like plastic sheet is incorporated into the sutures to create an open space beneath.
A slit is made in the plastic cover to afford the surgeon's hands access to the abdomen and pelvis whereby the surgeon can manipulate the viscera during the perfusion with the result that all of the anatomic structures within the peritoneal cavity are exposed to heat and to chemotherapy. Although this latter method and apparatus further solved some of the problems of prior art systems and techniques, the self-retaining retractor and tent-like plastic sheet preclude the ability to selectively and repeatedly open and close access to the abdomino-pelvic cavity, and to reliably prevent spillage of perfusion fluid or infiltration of the fluid's aerosols into the surrounding operating room environment, and thereby also limit its safe use.
Thus, it too precludes post-operative lavage coupled with the administration of intraperitoneal chemotherapy agents which achieve their optimal effect through long-term contact with the tissues.
Accordingly, there is a need for an abdomino-pelvic perfusion and lavage apparatus which is supported by an operating room table or bed upon which a patient is lying and which is sealed to the patient's anterior skin surface. It must allow for simple and secure suspension of the skin surrounding an incisional wound made through the abdominal wall. It must supply couplings for quick and easy connection of inflow and outflow tubes and temperature monitors through the wall of the apparatus.
There is also a need that such an apparatus be capable of being left in place after the patient leaves the operating room so that continuous perfusion or repeated lavaging can be performed in an aseptic condition using cell-cycle specific chemotherapy agents which require long-term contact with the target tissues.
Similarly, it is desirable that such an apparatus facilitate periodic manipulation of abdominal and pelvic contents and treatment in a surgical intensive care unit (SICU) without necessitating a further operation or even requiring further use of the operating room except to suture the abdomen closed. It is also desirable that the apparatus be sealable so that chemotherapy can be performed without danger of exposure of operating room and SICU personnel to chemotherapy aerosols.
Moreover, a further desired feature would include openings for free access to the peritoneal cavity for both visual inspection and for the introduction of a surgeon's hands for manipulation of the viscera. It is also desirable that there be couplings for 5 quick and easy mounting of an air evacuation system which can evacuate the chemotherapy aerosols when the appliance is opened.
Furthermore, since chemotherapy not only directly destroys tumor cells but also eliminates viable platelets, neutrophils and monocytes from the peritoneal cavity; the ability of the abdomen 10 to resist infection is reduced. Thus, it is imperative that the apparatus be adapted to maintain a strict aseptic environment when administering chemotherapy, handling abdominal tubes and drains, and during manipulation of the viscera.
SUMMARY OF THE INVENTION
The present invention is directed to an improved abdomino-pelvic perfusion and lavage apparatus adapted for use both during and after surgery and to which skin surrounding an incision formed through an abdominal wall of a patient can be attached and suspended. More particularly, the invention relates to an abdomino-pelvic perfusion and lavage apparatus for intraperitoneal treatment of diseases disseminated through the peritoneal cavity, and especially in the hyperthermic treatment of the peritoneal dissemination of gastrointestinal, ovarian and other intra-abdominal cancers. The invention especially allows the use of heat, coupled with manipulation of the organs, in peritoneal perfusion procedures and more particularly is adapted to be left in place after the patient leaves the operating room so that repeated lavaging can be performed using cell-cycle specific chemotherapy agents which require long-term contact with the target tissues. Additionally, by permitting repeated access to the abdominal cavity, the apparatus is adapted for non-oncologic use in the treatment of intra-abdominal sepsis, peritonitis and pancreatitis.
In one preferred embodiment the invention comprises a containment vessel impermeable to water and air, having a wall having a base, wherein the wall has an upper end with a perimeter edge which defines an upper opening, a lower end with a perimeter edge which defines a base opening, a cranial end with a perimeter edge which defines an opening, and a caudal end with a perimeter edge which defines an opening. A plurality of fluid ports which are capable of providing hydraulic and pneumatic communication through the wall of the containment vessel are also provided.
The containment vessel is adapted to be carried by a table on which the patient is positioned.
A further aspect of the invention comprises a scaffolding that is carried by the containment vessel for supporting and elevating the skin surrounding the incision made through the abdominal wall of the patient whereby said elevated skin forms a well above, and extending into, an abdomino-pelvic cavity.
A further aspect of the invention comprises a fluid supply reservoir which serves as a source for the perfusion fluid; a first pump in hydraulic communication with the fluid supply reservoir and at least one fluid port for providing the perfusion fluid from the source to the containment vessel; a second pump in hydraulic communication with the fluid supply reservoir and at least one fluid port for returning the perfusion fluid from the containment vessel back to the source; a heater in thermal communication with a fluid containing means to heat the perfusion fluid to a temperature of about 30 C to about 50 C during use of the containment vessel in hyperthermic peritoneal perfusion;
at least one inflow tube in hydraulic communication with the fluid port receiving the perfusion fluid from the source for providing the perfusion fluid to the well formed in the patient's abdomino-pelvic cavity; at least one drain tube in hydraulic communication with the fluid port returning the perfusion fluid to the source and having a distal intake end extended into the well in the patient's abdomino-pelvic cavity for providing the perfusion fluid from the well; at least one temperature sensor positioned in proximity with the distal intake end of the drain tube and in communication with a thermostatic control in communication with the heater.
A further aspect of the invention comprises at least one removable cover capable of being secured and sealed over the upper opening of the containment vessel to enclose the well formed therein, thereby forming a barrier to aerosols so that chemotherapy agents can be used without exposing personnel to chemotherapy aerosols, and whereby the containment vessel may be left in place on a patient who may then be returned to an WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 intensive care unit for follow-up examinations, continuous perfusion and repeated lavaging without introducing bacterial pathogens and without necessitating use of the operating room.
A further aspect of the invention comprises an air evacuator connected in pneumatic communication with one or more fluid ports to form a low air pressure gradient across the upper opening and thereby evacuate aerosols and gases from within the interior space whenever one or more of the sealable covers is open and thereby minimizing the risk of exposure of surgical and SICU
personnel to the chemotherapy aerosols and gases.
A further aspect of the invention comprises a plurality of port-seals for sealing hydraulic and pneumatic communication through any unused fluid ports. A cranial opening seal is also provided to seal hydraulic and pneumatic communication through the cranial opening between the containment vessel and a torso of the patient and a caudal opening seal is likewise provided to seal hydraulic and pneumatic communication through the caudal opening between the containment vessel and a torso of the patient. A base seal is provided to seal hydraulic and pneumatic communication between the containment vessel and the table.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a top perspective view showing a containment vessel according to the present invention, in position over a patient on an operating table, with a cover removed to reveal an upper opening through which a scaffolding is visible and to which a skin edge surrounding an abdominal incision has been elevated and sutured.
Fig. 2 is a top perspective view of the containment vessel depicted in Fig. 1, with the cover secured in place to close the upper opening, and the scaffolding in place and extending through sealable openings communicating through a wall of the containment vessel.
Fig. 3 is a top plan view of the containment vessel as depicted in Fig. 2, with the cover removed, and showing the scaffolding in place and extending through sealable openings communicating the wall of the containment vessel.
Fig. 4 is a right side elevational view of the containment vessel as depicted in Fig. 2, with the cover and scaffolding in place, the left side elevational view being substantially the same.
Fig. 5 is a front elevational view of the containment vessel as depicted in Fig. 2, with the cover and scaffolding in place, the rear elevational view being substantially the same.
Fig. 6 is a sectional view taken through line 6-6 of Fig.
4.
Fig. 7 is a top perspective view of the containment vessel depicted in Fig. 1 wherein a left side of the containment vessel has been cut away to better reveal the skin edges surrounding the abdominal incision which are elevated and sutured to the scaffolding thereby forming a well.
Fig. 8 is a partially schematic top plan view of the containment vessel of Figs. 1 and 2 in use with the cover removed WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 and the accessory devices connected in operative relationship.
Fig. 9 is a top plan view of an alternative embodiment of the containment vessel of the present invention, with the cover 5 removed, and wherein the scaffolding is carried by an inner surface of the wall of the containment vessel.
Fig. 10 is a top plan view of a further alternative embodiment of the containment vessel of the present invention, with the cover removed, and wherein the scaffolding is carried 10 by the inner surface of the wall of the containment vessel and is integral thereto.
Fig. 11 is a sectional view taken through line 11-11 of Fig.
10.
Fig. 12 is a top plan view of an alternative embodiment of 15 the containment vessel of the present invention wherein the scaffolding is a support ring supported by a suspension carried by the inner surface of the wall of the containment vessel.
Fig. 13 is a sectional view taken through line 13-13 of Fig.
12.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention comprises an apparatus for perfusing or lavaging the abdomino-pelvic cavity during or after surgery.
More particularly, the invention is directed to an abdomino-pelvic perfusion/lavage apparatus for treatment of diseases disseminated through the peritoneal cavity, and especially in the hyperthermic treatment of the peritoneal dissemination of gastrointestinal, ovarian and other intra-abdominal cancers. The invention especially allows the use of heat, coupled with manipulation of the organs, in peritoneal perfusion procedures. Additionally, the apparatus and method of the present invention can be used in conjunction with cell-cycle specific drugs so that a lavage fluid can be maintained in the abdomino-pelvic cavity for up to 5-10 days postoperatively for long-term exposure so that the chemotherapy agents achieve their optimal effect.
Any lavage fluid employed in the prior art can be used with the apparatus and method of the present invention.
Additionally, in patients with disease states like peritonitis and pancreatitis, it can be expected that the patient need not return to the operating room on numerous occasions in order to ensure that no sepsis remained, as is utilized in the "zipper" technique or in a gauze packing technique. The patient can merely be transferred to an SICU setting with the apparatus in place where continuous perfusion, repeated gauze packing, repeated inspection or repeated lavage of the abdominal cavity can be performed. Only when the abdominal or pelvic sepsis has resolved is surgical repair of the abdominal incision in the operating room required. Multiple return visits to the operating room are to be avoided in this new approach.
The apparatus of the present invention is adapted to be supported by an operating table or other generally planar surface which also supports a patient and to elevate and secure skin around a midline abdominal incision. The apparatus comprises an open-ended containment vessel with means for supporting the skin edges surrounding the incision thereby forming a well for containing a perfusion/lavage fluid used to treat the surfaces of the patient's abdomen and pelvis. For gastrointestinal and gynecologic cancer patients, this includes a majority of sites at risk for local recurrence and peritoneal seeding. Heated perfusion fluid with anti-cancer drugs can be added until the well formed in the abdominal and pelvic cavities is completely filled with the chemotherapy solution.
In the preferred embodiment of the present invention the apparatus is adapted to be used with a cover securable over the upper end of the containment vessel to thereby confine chemotherapy aerosols and thereby maintain the operating room and postanesthesia care unit environments safe for personnel during the administration of chemotherapy. Additionally, the apparatus is also adapted to be used with its upper end open. The cover, when used, can include one or more additional smaller openings which permit the surgeon to have access to the abdominal cavity for additional functions such as: visual inspections, making incisions, further cytoreduction, excising structures, suturing, selective positioning of the inflow and outflow tubes and temperature sensing devices, and for manual manipulation of the intra-abdominal organs so that all fibrinous accumulations that can harbor cancer cells are disbursed. In cancer patients this also allows manual debridement of the narrow margins of the WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 excision, manipulation of all peritoneal crevices, and visual inspection of all bowel surfaces. Since chemotherapy not only directly destroys tumor cells but also eliminates viable platelets, neutrophils and monocytes from the peritoneal cavity the ability of the abdomen to resist infection is reduced.
Accordingly, the apparatus of the present invention is also adapted to maintain a strict aseptic environment.
Sealable ports along the wall of the containment vessel provide selective connection of inflow and outflow tubes for passage of the lavage fluid, and for temperature sensing devices extended into the abdominal cavity.
Further sealable ports along the wall of the containment vessel also provide for the selective connection of an air evacuation device and thus permit the evacuation of chemotherapy aerosols, from the interior space within the containment vessel, through the wall of the containment vessel whenever one of the access openings is open without imposing physical interference to the surgeon's access.
In a preferred embodiment the perfusion fluid is heated by use of a heater and circulated by a pair of peristaltic pumps such as found in a conventional heart-lung machine. A single inflow tube is used for supplying the perfusion fluid to the well in the abdominal cavity; and one, two, three or more drain tubes are used for draining the perfusion fluid from the abdominal cavity's well.
In one preferred embodiment one drain tube is placed beneath the patient's right hemidiaphragm, one beneath the left hemidiaphragm and the other in the pelvic cavity. If the chest cavity is entered through an incision in the diaphragm, a fourth drain tube, a chest tube, can also be used. The drain tubes should be moderately stiff, with multiple side openings, and a heat sensor should be associated with the distal end of each for monitoring the temperature of the perfusion fluid, in situ, throughout the procedure.
Sampling of the perfusion fluid drained from the abdominal cavity can be performed throughout the procedure so that the absorption of chemotherapy can be ascertained, and a geiger counter can be located over the abdomen so that any absorption from the abdomen into the systemic circulation can be estimated.
This is accomplished with the use of radioactive technetium, which may or may not be attached to various molecules such as albumin. A counter over the heart can also be used to enable the amount of absorption from the abdomino-pelvic cavity to be documented in an on-line manner. Simultaneous readings in the abdominal cavity and over the heart thus enable the absorption of chemotherapy to be estimated and a maximum systemic dosage of drug delivered with the surgical or post-operative event.
The containment vessel is preferably made of a lightweight, but strong, plastic material which is impervious to water and air, such as Ultem T ' made by General Electric Company, with an elliptical shape in transverse cross-section. It and other components of the apparatus can be made disposable if desired.
To facilitate disposal of the used containment vessel, it can be scored at intervals to define fracture lines. The containment vessel can be made in several different sizes to accommodate different size patients and different size abdominal incisions.
5 In the preferred embodiments of the present invention a scaffolding can be affixed to the containment vessel for supporting and elevating the skin edges surrounding an incision made through the abdominal wall of the patient whereby the elevated skin forms a well above, and extending into, an 10 abdomino-pelvic cavity. The skin edges surrounding the incision are elevated and connected to the scaffolding by sutures or other connecting means.
In a first alternative embodiment a series of rods are placed through sealable openings near the upper end of the 15 containment vessel. A second embodiment uses a series of rods carried by the inner surface of the wall of the containment vessel. A third embodiment uses a scaffolding formed integrally with the inner surface of the wall of the containment vessel.
A fourth embodiment utilizes a support ring which can be 20 elevated and hung from a suspension carried by the inner surface or the upper edge of the wall of the containment vessel. The support ring can be in the form of either an open loop or a closed loop. It can be connected to the skin edges surrounding the incision either wholly before being suspended from the suspension, wholly after being suspended from the suspension or partially before and partially after being suspended from the WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 suspension.
The present invention has particular application where use of cell-cycle specific chemotherapy agents is desirable. An initial irrigation with a fibrinolytic agent can be first performed with the cover removed and the abdominal well open to the atmosphere. During this initial procedure all debris, cancer cells and fibrinous material can be flushed from the peritoneal cavity. Following the initial irrigation, the cover can be placed on top of the containment vessel and all fibrinolytic phase fluid can be removed from the abdomino-pelvic cavity. An irrigation with a heated chemotherapy solution can then be conducted. In the preferred embodiment of the present invention if the chemotherapy agent includes a cell-cycle specific drug, the patient, with the apparatus of the present invention remaining in place, can be transferred to a SICU where a lavage procedure can be maintained for up to 5-10 days without the need to return to the operating room except to close the abdomen at the end of the chemotherapy treatment. By using the apparatus of the present invention, the surgeon is able to re-enter the abdominal cavity with a greatly reduced risk of exposure of operating room personnel to chemotherapy aerosols. During this time, the surgeon can also manually debride the narrow margins of the excision, manipulate the peritoneal crevices, and visually inspect all bowel surfaces. After the lavage procedure is finally completed the surgeon is then able to perform all reconstructive procedures, such as bowel anastomoses and closure of the surgical incision.
The abdomino-pelvic lavage apparatus of the present invention can have uses other than in oncology. For instance, it can be used for treatment of patients with intra-abdominal sepsis by irrigating the abdominal cavity with antibiotic and fibrinolytic agents. In this way, all of the infected fibrin can be removed from the abdominal cavity. By the repeated manipulation of the abdominal contents and repeated irrigation of the abdominal cavity, pathogens will be dislodged whereby bacterial counts can be brought down to an extremely low level.
The additional time that the lavage fluid is permitted to be present in the abdominal cavity by use of the invention can be of great value in eliminating sources of bacterial or fungus infection. With the removal of all contaminated fibrinous material, the patient can be expected to improve more quickly from surgery.
The foregoing aspects and many of the attendant advantages of the present invention will become more readily appreciated to those skilled in the art as the same becomes better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein like reference characters designate like parts throughout the several views.
Referring more specifically to the drawings, a first embodiment of the present invention of improved abdomino-pelvic chemotherapy perfusion and lavage apparatus 20 is indicated in WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 Fig. 1. In this embodiment of the invention a containment vessel 22 having a generally elliptical shape in transverse cross-section with a longitudinal axis 24, is made of a material, preferably plastic, impervious to air and water. An upper perimeter edge 26 of a wall 28 defines an upper opening 30 in containment vessel 22. Containment vessel 22 is adapted to be carried by a table 32 on which a patient 34 is positioned. An absorbent-material blanket 36, which has a moisture-resistant membrane on one side, is extended laterally beyond patient 34 and is disposed between the bottom of wall 28 and table 32. As so disposed, absorbent-material blanket 36 forms an air and watertight seal between the bottom of wall 28 of containment vessel 22 and table 32.
Referring now to Fig. 2, a lower perimeter edge 38 of wall 28 defines a lower opening 40 (visible in Figs 5 and 6) . One or more sealable covers 42 can be placed over upper opening 30 of containment vessel 22. A plurality of sealable inflow ports 44, a plurality of sealable outflow ports 46, and a plurality of sealable vacuum ports 48 are disposed at spaced locations around the circumference of wall 28 and communicate through wall 28.
In the particular embodiment shown, a plurality of sealable openings 50 are also disposed at spaced locations along the upper portion of wall 28 and also communicate through said wall 28.
As is seen in Fig. 3, wall 28 has an inner surface 52 and an outer surface 54. In the embodiment shown, a plurality of rods 56 is placed through the plurality of sealable openings 50 24 CA 02390476 2002-05-07 pCT/US00/30923 and as thus disposed said rods 56 form a scaffolding 58 disposed between the oppositely facing surfaces of inner surface 52 of wall 28.
Referring now to Figs. 4-6, in the preferred embodiment of the present invention containment vessel 22 has a cranial end 60 with an opening 62 defined by a generally semi-elliptical perimeter edge 64; and a caudal end 66 with an opening 68 defined by a generally semi-elliptical perimeter edge 70. A first seal 72, preferably made of a pliable membrane material which is impervious to water and air, is disposed along perimeter edge 64 of opening 62. A similar second seal 74 is disposed along perimeter edge 70 of opening 68.
Referring back to Fig. 1, cranial opening 62 and caudal opening 68 are of sufficient size such that when in use containment vessel 22 straddles patient 34 while patient 34 is disposed in lower opening 40 of containment vessel 22 and such that the bottom of wall 28 of containment vessel 22 is carried by table 32 while perimeter edge 64 and perimeter edge 70 are disposed at a proper height above and proximate to, but not in contact with, patient 34. Patient 34's upper torso 76 is disposed in cranial opening 62 and patient 34's lower torso 78 is disposed in caudal opening 68. As thus disposed, first seal 72 seals cranial opening 62 around upper torso 76 and thereby forms an air and watertight seal in cranial opening 62. Second seal 74 likewise seals caudal opening 68 around lower torso 78 and thereby an air and watertight seal in caudal opening 68.
WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 Referring now to Fig. 7, which is a cut-away view of Fig.
1 wherein a portion of wall 28 of containment vessel 22 has been cut away and removed so as to provide a view into containment vessel 22, scaffolding 58 is disposed superior to patient 34's 5 abdominal area 80 surrounding where an incision 82 has been made or is intended to be made. After incision 82 is made in patient 34's abdominal area 80, a running suture 84 is secured through skin edge 86 surrounding incision 82. As each suture 84 is secured to skin edge 86 said suture 84 and the skin edge 86 10 attached thereto are vertically displaced upwardly by a surgeon (not shown) and as thus vertically displaced are disposed and secured to scaffolding 58 which then supports skin edge 86 in a vertically superior position relative to patient 34. After all sutures 84 are completed, the displacement of skin edge 86 15 thereby forms a well 88 above and extending into abdomino-pelvic cavity 90.
Referring now to Fig. 8, perfusion fluid is provided from supply reservoir 92 through one or more of sealable inflow ports 44 communicating through wall 28 to well 88 formed in abdomino-20 pelvic cavity 90. Fluid is withdrawn from well 88 through one or more of sealable outflow ports 46 and returned to supply reservoir 92.
The perfusion fluid is pumped from supply reservoir 92 by first pump 94 connected in hydraulic communication with supply 25 reservoir 92 and one or more of sealable inflow ports 44. A
second pump 96 connected in hydraulic communication with one or WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 more of sealable outflow ports 46 and supply reservoir 92 returns the fluid to supply reservoir 92. During use of apparatus 20 in hyperthermic peritoneal perfusion, a heater 98 heats the fluid to a temperature of about 30 C to about 50 C and preferably about 40 C to about 50 C and ideally about 44 C to about 46 C
so as to maintain the temperature of the fluid in well 88 of abdomino-pelvic cavity 90 at about 42.5 C.
An inflow tube 100, which is connected in hydraulic communication with the at least one sealable inflow port 44 which is connected in hydraulic communication with supply reservoir 92 and first pump 94, delivers the fluid to well 88. At least one drain tube 102, which is connected in hydraulic communication with the at least one sealable outflow port 46 connected in hydraulic communication with supply reservoir 92 and second pump 96, withdraws the chemotherapy solution from well 88 through its distal intake end 104.
In the preferred embodiment shown in Fig. 8 there are three drain tubes 102 having distal intake ends 104 extended into well 88 and abdomino-pelvic cavity 90. Distal intake end 104 of a first drain tube 102 is disposed beneath a left hemidiaphragm 106 of patient 34, distal intake end 104 of a second drain tube 102 is disposed beneath a right hemidiaphragm 108 of patient 34, and distal intake end 104 of a third drain tube 102 is disposed in a pelvis 110 of patient 34. If the chest cavity 112 of the patient 34 is also opened, a fourth drain tube (not shown) , being a chest tube, can be disposed having its distal intake end (not WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 shown) in chest cavity 112.
One or more temperature sensors 114 are disposed in close proximity with the distal intake end 104 of each drain tube 102 to measure the temperature of the perfusion fluid within abdomino-pelvic cavity 90, said temperature sensors 114 communicating to a thermostatic control 116 connected to heater 98.
In use longitudinal axis 24 of containment vessel 22 is axially aligned with patient 34. As thus aligned, containment vessel 22 is placed over abdominal area 80 surrounding where incision 82 is to be made.
In use during chemotherapy one or more selectively removable and sealable covers 42 (as shown in Fig. 2) are disposed over upper opening 30 of containment vessel 22 thereby enclosing an interior space 118 (visible in Figs. 1 and 7) within containment vessel 22 and thus encasing well 88. As shown in Fig. 8, air evacuator 120 is connected in pneumatic communication with one or more of sealable vacuum ports 48 to form an air pressure gradient across the upper opening 30 and when activated thereby evacuates aerosols and gases 122 from within interior space 118 whenever one or more of sealable covers 42 is open thereby minimizing the risk of exposure of surgical and SICU personnel (not shown) to the chemotherapy aerosols and gases 122.
Any unused inflow ports 44, outflow ports 46, vacuum ports 48, and openings 50 can be sealed by conventional capping or plugging means thereby forming a barrier to the chemotherapy aerosols and gases 122 so that chemotherapy agents can be used without exposing personnel to the chemotherapy aerosols and gases 122. By leaving sealable covers 42 in place and sealing unused inflow ports 44, outflow ports 46, vacuum ports 48, and openings 50, containment vessel 22 can also maintain an aseptic environment and thus be left in place on patient 34 who may then be returned to a surgical intensive care unit for follow-up examination and treatment. Maintenance of intraperitoneal lavage, repeated inspection and repeated lavage procedures can thus be accomplished without necessitating return to the operating room.
In one preferred embodiment shown in Figs. 1-8, one sealable inflow port 44 and two sealable outflow ports 46 are disposed at cranial end 60 of containment vessel 22. Similarly, one sealable inflow port 44 and two sealable outflow ports 46 are disposed at caudal end 66 of containment vessel 22.
In an alternative embodiment shown in Fig. 9, a plurality of rods 124 are carried by supports 126 disposed on the inner surface 52 of wall 28 thereby forming an interior support scaffolding 128.
In another alternative embodiment shown in Figs. 10 and 11, an integral support scaffolding 130 is integrally formed with inner surface 52 of wall 28.
In yet another alternative embodiment shown in Figs. 12 and 13, a closed loop support ring 132, which in use defines the shape of an open end of well 88, is disposed and suspended from a suspension 134 carried by the inner surface 52 of wall 28. In a further alternative embodiment support ring 132 can be in the form of an open loop. In the embodiment shown, support ring 132 can be placed on patient 34's abdominal area 80 surrounding incision 82. Skin edge 86 surrounding incision 82 can be affixed by sutures 84 or other connecting means to support ring 132.
Support ring 132, together with skin edge 86 connected thereto, can then be vertically displaced upwardly by the surgeon (not shown) to a vertically superior position and suspended from suspension 134 thereby forming well 88 above and extending into abdomino-pelvic cavity 90.
In an alternative embodiment, support ring 132 can be suspended from suspension 134 prior to being connected to skin edge 86. In yet another alternative embodiment support ring 132 can be partially connected to skin edge 86 before being suspended from suspension 134 and partially connected to skin edge 86 after being suspended from suspension 134.
In yet another embodiment, suspension 134 can be carried by upper perimeter edge 26 of a wall 28.
The invention thus provides a simple and effective apparatus for continuous perfusion and repeated lavage procedures in the abdomino-pelvic cavity, and especially an apparatus which enables the surgeon free and repeated access to the abdomino-pelvic cavity during the perfusion/lavage process and which permits accurate monitoring and control of temperature within the abdomino-pelvic cavity during treatment, particularly during WO 01/34224 CA 02390476 2002-05-07 pCT/US00/30923 hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination of intra-abdominal cancers and other related clinical situations. Additionally, by permitting repeated access to the abdominal cavity, the apparatus is adapted for non-5 oncologic use in the management of serious intra-abdominal infections and treatment of intra-abdominal sepsis, peritonitis and pancreatitis.
Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in 10 the art will appreciate that various modifications, additions and substitutions are possible without departing from the scope and spirit of the invention as disclosed in the accompanying claims.
Additionally, although in the preferred embodiments the shape of the containment vessel and the edges of the cranial and caudal 15 openings are described as elliptical and semi-elliptical, respectively, those skilled in the art will appreciate that these shapes can also be circular, rectangular, or compound shapes.
Claims (37)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An abdomino-pelvic perfusion and lavage apparatus to which skin surrounding an incision made through an abdominal wall of a patient can be attached and suspended, comprising:
a containment vessel impermeable to water and air, having a wall having a base, wherein the wall has an upper end with a perimeter edge which defines an upper opening, a lower end with a perimeter edge which defines a base opening, a cranial end with a perimeter edge which defines an opening, a caudal end with a perimeter edge which defines an opening; a plurality of fluid ports capable of providing fluid communication through the wall of the containment vessel; said containment vessel being capable of being carried by a table on which the patient is positioned; and a scaffolding carried by the containment vessel for supporting and elevating the skin surrounding the incision made through the abdominal wall of the patient, said elevated skin forming a well above, and extending into, an abdomino-pelvic cavity.
a containment vessel impermeable to water and air, having a wall having a base, wherein the wall has an upper end with a perimeter edge which defines an upper opening, a lower end with a perimeter edge which defines a base opening, a cranial end with a perimeter edge which defines an opening, a caudal end with a perimeter edge which defines an opening; a plurality of fluid ports capable of providing fluid communication through the wall of the containment vessel; said containment vessel being capable of being carried by a table on which the patient is positioned; and a scaffolding carried by the containment vessel for supporting and elevating the skin surrounding the incision made through the abdominal wall of the patient, said elevated skin forming a well above, and extending into, an abdomino-pelvic cavity.
2. The abdomino-pelvic perfusion and lavage apparatus of claim 1, wherein said scaffolding comprises: a support ring for connecting to the skin surrounding the incision made through the abdominal wall of the patient; at least one connector connectively disposed between the skin surrounding the incision made through the abdominal wall of the patient and the support ring; a suspension for carrying said support ring disposed superior to the patient's abdominal wall and carried by the wall of the containment vessel; wherein said support ring defines the shape of an open upper end of the well formed by said skin when said support ring is suspended from the suspension.
3. The abdomino-pelvic perfusion and lavage apparatus of claim 2, wherein said suspension is carried by an inner surface of the wall of the containment vessel.
4. The abdomino-pelvic perfusion and lavage apparatus of claim 2, wherein said suspension is carried by the perimeter edge of the upper end of the wall of the containment vessel.
5. The abdomino-pelvic perfusion and lavage apparatus of claim 2, wherein said support ring forms a closed loop.
6. The abdomino-pelvic perfusion and lavage apparatus of claim 2, wherein said support ring forms an open loop.
7. The abdomino-pelvic perfusion and lavage apparatus of claim 2, wherein said support ring can be connected to the skin surrounding the incision made through the abdominal wall of the patient before said support ring is suspended from the suspension.
8. The abdomino-pelvic perfusion and lavage apparatus of claim 2, wherein said support ring can be connected to the skin surrounding the incision made through the abdominal wall of the patient after said support ring is suspended from the suspension.
9. The abdomino-pelvic perfusion and lavage apparatus of claim 2, wherein: said support ring can be fully or partially connected to the skin surrounding the incision made through the abdominal wall of the patient before said support ring is suspended from the suspension; and said support ring can be fully or partially connected to the skin surrounding the incision made through the abdominal wall of the patient after said support ring is suspended from the suspension.
10. The abdomino-pelvic perfusion and lavage apparatus of claim 1, wherein said scaffolding comprises: a support structure disposed around an interior perimeter of the wall of the containment vessel superior to the patient's abdominal wall; and at least one connector connectively disposed between the skin surrounding the incision made through the abdominal wall of the patient and the support structure.
11. The abdomino-pelvic perfusion and lavage apparatus of claim 10, wherein said support structure frames the incision made through the abdominal wall of the patient.
12. The abdomino-pelvic perfusion and lavage apparatus of claim 10, wherein said support structure is comprised of rods inserted through a plurality of sealable openings communicating through the wall of the containment vessel.
13. The abdomino-pelvic perfusion and lavage apparatus of claim 12, further comprising a plurality of opening seals for forming air and watertight seals in said plurality of sealable openings thereby forming a barrier to aerosols so that chemotherapy can be used without exposing personnel to chemotherapy aerosols, and so that the containment vessel can be left in place on a patient who can then be returned to a surgical intensive care unit for follow-up examinations and repeated lavage procedures without necessitating use of the operating room except for closure of the incision made through the abdominal wall of the patient.
14. The abdomino-pelvic perfusion and lavage apparatus of claim 10, wherein said support structure is comprised of rods carried by an inner surface of the wall of the containment vessel.
15. The abdomino-pelvic perfusion and lavage apparatus of claim 10, wherein said support structure is integral with an inner surface of the wall of the containment vessel.
16. The abdomino-pelvic perfusion and lavage apparatus of claim 1, wherein hydraulic communication can be established through at least one of said plurality of fluid ports.
17. The abdomino-pelvic perfusion and lavage apparatus of claim 16, wherein: at least one of said plurality of fluid ports further comprises at least one inflow port; and at least one of said plurality of fluid ports further comprises at least one outflow port.
18. The abdomino-pelvic perfusion and lavage apparatus of claim 17, further comprising: a fluid supply reservoir; a first pump in hydraulic communication with the fluid supply reservoir and the at least one inflow port to provide perfusion fluid from the supply reservoir to the containment vessel; a second pump in hydraulic communication with the fluid supply reservoir and the at least one outflow port to provide the perfusion fluid from the containment vessel back to the supply reservoir; and a heater in thermal communication with a fluid containing means to heat the perfusion fluid to a temperature of about 30° C to about 50°
C during use of the containment vessel in hyperthermic peritoneal perfusion.
C during use of the containment vessel in hyperthermic peritoneal perfusion.
19. The abdomino-pelvic perfusion and lavage apparatus of claim 18, further comprising: at least one inflow tube connected to the at least one inflow port for providing the perfusion fluid to a well formed in an abdomino-pelvic cavity; and at least one drain tube connected to the at least one outflow port having a distal intake end extended into the abdomino-pelvic cavity of the patient for providing the perfusion fluid from the well formed in the abdomino-pelvic cavity.
20. The abdomino-pelvic perfusion and lavage apparatus of claim 19, further comprising: at least one temperature sensor positioned in proximity with the distal intake end of the at least one drain tube, said at least one temperature sensor being in communication with a thermostatic control;
and said thermostatic control being in communication with said heater.
and said thermostatic control being in communication with said heater.
21. The abdomino-pelvic perfusion and lavage apparatus of claim 1, further comprising: at least one removable cover capable of being secured and sealed over the upper opening of the containment vessel to enclose a well formed therein, thereby forming a barrier to aerosols so that chemotherapy can be used without exposing personnel to chemotherapy aerosols, and so that the containment vessel can be left in place on a patient who can then be returned to an intensive care unit for follow-up examinations and repeated lavage procedures without introducing bacterial pathogens and without necessitating use of the operating room except for closure of the incision made through the abdominal wall of the patient.
22. The abdomino-pelvic perfusion and lavage apparatus of claim 1, further comprising at least one seal forming an air and watertight seal between the containment vessel and a torso of the patient, thereby forming a barrier to aerosols so that chemotherapy can be used without exposing personnel to chemotherapy aerosols, and so that the containment vessel can be left in place on a patient who can then be returned to an intensive care unit for follow-up examinations and repeated lavage procedures without introducing bacterial pathogens and without necessitating use of the operating room except to close the incision made through the abdominal wall of the patient.
23. The abdomino-pelvic perfusion and lavage apparatus of claim 22, wherein said at least one seal further comprises:
a first seal disposed proximate to the perimeter edge of the cranial opening; and a second seal disposed proximate to the perimeter edge of the caudal opening.
a first seal disposed proximate to the perimeter edge of the cranial opening; and a second seal disposed proximate to the perimeter edge of the caudal opening.
24. The abdomino-pelvic perfusion and lavage apparatus of claim 1, further comprising: a base seal disposed proximate to the base of the containment vessel, said base seal forming an air and watertight seal between the containment vessel and the table, thereby forming a barrier to aerosols so that chemotherapy can be used without exposing personnel to chemotherapy aerosols, and so that the containment vessel can be left in place on a patient who can then be returned to a surgical intensive care unit for follow-up examinations and repeated lavage procedures without introducing bacterial pathogens and without necessitating use of the operating room except to close the incision made through the abdominal wall of the patient.
25. The abdomino-pelvic perfusion and lavage apparatus of claim 1, wherein pneumatic communication can be established through at least one of said plurality of fluid ports.
26. The abdomino-pelvic perfusion and lavage apparatus of claim 25, further comprising an air evacuation means, in pneumatic communication with said at least one of said plurality of fluid ports, for removing chemotherapy aerosols from within the containment vessel.
27. The abdomino-pelvic perfusion and lavage apparatus of claim 26, wherein said air evacuation means is a smoke evacuator system.
28. The abdomino-pelvic perfusion and lavage apparatus of claim 1 wherein the plurality of fluid ports are sealable.
29. The abdomino-pelvic perfusion and lavage apparatus of claim 28 further comprising a plurality of port-seals for selectively sealing the plurality of fluid ports thereby forming a barrier to aerosols so that chemotherapy can be used without exposing personnel to chemotherapy aerosols, and the containment vessel can be left in place on a patient who can then be returned to an intensive care unit for follow-up examinations and repeated lavage procedures without introducing bacterial pathogens and without necessitating use of the operating room except to close the incision made through the abdominal wall of the patient.
30. An abdomino-pelvic perfusion and lavage apparatus to which skin surrounding an incision made through an abdominal wall of a patient can be attached and suspended, comprising:
a containment vessel impermeable to water and air, having a wall having a base, wherein the wall has an upper end with a perimeter edge which defines an upper opening, a lower end with a perimeter edge which defines a base opening, a cranial end with a perimeter edge which defines an opening, a caudal end with a perimeter edge which defines an opening;
a plurality of fluid ports capable of providing fluid communication through the wall of the containment vessel;
said containment vessel being capable of being carried by a table on which the patient is positioned; a scaffolding carried by the containment vessel for supporting and elevating the skin surrounding the incision made through the abdominal wall of the patient whereby said elevated skin forms a well above, and extending into, an abdomino-pelvic cavity; at least one removable cover capable of being secured and sealed over the upper opening of the containment vessel to enclose the well formed therein, thereby forming a barrier to aerosols so that chemotherapy can be used without exposing personnel to chemotherapy aerosols, and the containment vessel can be left in place on a patient who can then be returned to an intensive care unit for follow-up examinations and repeated lavage procedures without introducing bacterial pathogens and without introducing bacterial pathogens and without necessitating use of the operating room except to close the incision made through the abdominal wall of the patient; a plurality of port-seals for sealing the plurality of fluid ports; a first seal disposed proximate to the perimeter edge of the cranial opening to seal fluid communication between the containment vessel and a torso of the patient; a second seal disposed proximate to the perimeter edge of the caudal opening to seal fluid communication between the containment vessel and a torso of the patient; and a base seal disposed proximate to the base of the containment vessel to seal fluid communication between the containment vessel and the table.
a containment vessel impermeable to water and air, having a wall having a base, wherein the wall has an upper end with a perimeter edge which defines an upper opening, a lower end with a perimeter edge which defines a base opening, a cranial end with a perimeter edge which defines an opening, a caudal end with a perimeter edge which defines an opening;
a plurality of fluid ports capable of providing fluid communication through the wall of the containment vessel;
said containment vessel being capable of being carried by a table on which the patient is positioned; a scaffolding carried by the containment vessel for supporting and elevating the skin surrounding the incision made through the abdominal wall of the patient whereby said elevated skin forms a well above, and extending into, an abdomino-pelvic cavity; at least one removable cover capable of being secured and sealed over the upper opening of the containment vessel to enclose the well formed therein, thereby forming a barrier to aerosols so that chemotherapy can be used without exposing personnel to chemotherapy aerosols, and the containment vessel can be left in place on a patient who can then be returned to an intensive care unit for follow-up examinations and repeated lavage procedures without introducing bacterial pathogens and without introducing bacterial pathogens and without necessitating use of the operating room except to close the incision made through the abdominal wall of the patient; a plurality of port-seals for sealing the plurality of fluid ports; a first seal disposed proximate to the perimeter edge of the cranial opening to seal fluid communication between the containment vessel and a torso of the patient; a second seal disposed proximate to the perimeter edge of the caudal opening to seal fluid communication between the containment vessel and a torso of the patient; and a base seal disposed proximate to the base of the containment vessel to seal fluid communication between the containment vessel and the table.
31. The abdomino-pelvic perfusion and lavage apparatus according to claim 1 or 30, wherein the upper opening is of sufficient size to allow for insertion of a surgeon's hands into the abdomino-pelvic cavity for manipulation of the perfusion fluid and intra-abdominal tissues, debridement of narrow margins of excisions, and removal of fibrinous accumulations and visually inspection of all bowel surfaces.
32. Use of the apparatus according to any one of claims 1 to 31, for perfusion, lavage and irrigation of an abdomino-pelvic cavity of a patient having an incision through the abdominal wall with perfusion fluid.
33. Use of the apparatus according to any one of claims 1 to 31 for perfusion, lavage and irrigation of an abdomino-pelvic cavity of a patient having an incision through the abdominal wall with perfusion fluid, wherein said perfusion fluid is for introduction into a well formed above and extending into the abdomino-pelvic cavity through said wall of the containment vessel.
34. The use according to claim 33, wherein the perfusion fluid comprises drugs.
35. The use according to claim 33 or 34, wherein the containment vessel further comprises a cover over the containment vessel.
36. The use according to claimed in claim 35, wherein the containment vessel comprises a means for evacuating aerosols and gasses from an interior space within the containment vessel when the cover is opened.
37. The use according to claim 34, wherein the temperature of the perfusion fluid increases the toxicity of the drugs.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/438,479 US6383162B1 (en) | 1999-11-12 | 1999-11-12 | Apparatus and method for abdomino-pelvic chemotherapy perfusion and lavage |
US09/438,479 | 1999-11-12 | ||
PCT/US2000/030923 WO2001034224A1 (en) | 1999-11-12 | 2000-11-09 | Apparatus and method for abdomino-pelvic chemotherapy perfusion and lavage |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2390476A1 CA2390476A1 (en) | 2001-05-17 |
CA2390476C true CA2390476C (en) | 2008-10-07 |
Family
ID=23740810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002390476A Expired - Fee Related CA2390476C (en) | 1999-11-12 | 2000-11-09 | Apparatus and method for abdomino-pelvic chemotherapy perfusion and lavage |
Country Status (5)
Country | Link |
---|---|
US (1) | US6383162B1 (en) |
EP (1) | EP1231954A4 (en) |
AU (1) | AU769641B2 (en) |
CA (1) | CA2390476C (en) |
WO (1) | WO2001034224A1 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0011202D0 (en) * | 2000-05-09 | 2000-06-28 | Kci Licensing Inc | Abdominal wound dressing |
US7473221B2 (en) | 2000-10-19 | 2009-01-06 | Applied Medical Resources Corporation | Surgical access apparatus and method |
EP1416981B1 (en) | 2001-08-14 | 2013-07-24 | Applied Medical Resources Corporation | Access sealing apparatus |
US6958037B2 (en) | 2001-10-20 | 2005-10-25 | Applied Medical Resources Corporation | Wound retraction apparatus and method |
US7052454B2 (en) * | 2001-10-20 | 2006-05-30 | Applied Medical Resources Corporation | Sealed surgical access device |
CA2426481A1 (en) * | 2001-10-20 | 2003-05-01 | Applied Medical Resources Corporation | Sealed surgical access device |
EP2343031B1 (en) * | 2002-06-05 | 2013-08-07 | Applied Medical Resources Corporation | Wound retractor |
US20050020884A1 (en) | 2003-02-25 | 2005-01-27 | Hart Charles C. | Surgical access system |
JP2007516860A (en) | 2003-08-06 | 2007-06-28 | アプライド メディカル リソーシーズ コーポレイション | Non-adhesive surgical instrument with gel and manufacturing method |
US7163510B2 (en) * | 2003-09-17 | 2007-01-16 | Applied Medical Resources Corporation | Surgical instrument access device |
US9801527B2 (en) | 2004-04-19 | 2017-10-31 | Gearbox, Llc | Lumen-traveling biological interface device |
US8092549B2 (en) * | 2004-09-24 | 2012-01-10 | The Invention Science Fund I, Llc | Ciliated stent-like-system |
US8353896B2 (en) | 2004-04-19 | 2013-01-15 | The Invention Science Fund I, Llc | Controllable release nasal system |
US8337482B2 (en) * | 2004-04-19 | 2012-12-25 | The Invention Science Fund I, Llc | System for perfusion management |
US9011329B2 (en) | 2004-04-19 | 2015-04-21 | Searete Llc | Lumenally-active device |
US7998060B2 (en) * | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling delivery device |
US7850676B2 (en) * | 2004-04-19 | 2010-12-14 | The Invention Science Fund I, Llc | System with a reservoir for perfusion management |
US8019413B2 (en) | 2007-03-19 | 2011-09-13 | The Invention Science Fund I, Llc | Lumen-traveling biological interface device and method of use |
US7857767B2 (en) * | 2004-04-19 | 2010-12-28 | Invention Science Fund I, Llc | Lumen-traveling device |
US8361013B2 (en) * | 2004-04-19 | 2013-01-29 | The Invention Science Fund I, Llc | Telescoping perfusion management system |
US20060149137A1 (en) * | 2005-01-05 | 2006-07-06 | Applied Medical Resources Corporation | Easily placeable and removable wound retractor |
US20070000501A1 (en) * | 2005-07-01 | 2007-01-04 | Wert Lindsay T | Surgical procedure supplemental accessory controller and method utilizing turn-on and turn-off time delays |
US7704207B2 (en) | 2005-10-14 | 2010-04-27 | Applied Medical Resources Corporation | Circular surgical retractor |
US20070135761A1 (en) * | 2005-12-09 | 2007-06-14 | Cheng Kai-Sheng | Breast pump |
US20120035438A1 (en) | 2006-04-12 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Path selection by a lumen traveling device in a body tub tree based on previous path |
US8551075B2 (en) | 2006-06-02 | 2013-10-08 | Kci Medical Resources | Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing |
US7699831B2 (en) | 2006-06-02 | 2010-04-20 | Surgical Design Solutions, Llc | Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing |
US8715267B2 (en) | 2006-06-02 | 2014-05-06 | Kci Medical Resources | Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing |
US20080097562A1 (en) * | 2006-10-19 | 2008-04-24 | Dyamed Biotech Pte Ltd | System For Chemohyperthermia Treatment |
CN100542629C (en) * | 2006-12-31 | 2009-09-23 | 南京恒埔伟业科技股份有限公司 | Horizontal electric field RF heat therapy equipment |
EP2146643A4 (en) | 2007-05-11 | 2012-05-30 | Applied Med Resources | Surgical retractor with gel pad |
EP2719340B1 (en) | 2007-05-11 | 2017-02-08 | Applied Medical Resources Corporation | Surgical retractor |
CA2711116C (en) * | 2008-01-22 | 2017-08-29 | Applied Medical Resources Corporation | Surgical instrument access device |
CN102137688B (en) * | 2008-09-18 | 2014-01-22 | 凯希特许有限公司 | Therapy delivery systems and methods |
CA2739910C (en) | 2008-10-13 | 2017-06-06 | Applied Medical Resources Corporation | Single port access system |
US8216197B2 (en) * | 2008-10-29 | 2012-07-10 | Kci Licensing, Inc | Medical canister connectors |
US8114126B2 (en) | 2008-10-29 | 2012-02-14 | Kci Licensing, Inc. | Modular, reduced-pressure, wound-closure systems and methods |
ES2776949T3 (en) | 2009-08-31 | 2020-08-03 | Applied Med Resources | Multifunctional Surgical Access System |
US8499764B2 (en) | 2010-05-26 | 2013-08-06 | The Invention Science Fund I, Llc | Portable apparatus for establishing an isolation field |
CN201798846U (en) * | 2010-09-26 | 2011-04-20 | 西安好博士医疗科技有限公司 | Coelom circulation thermal-chemotherapy perfusion system |
EP2621348B1 (en) | 2010-10-01 | 2019-06-12 | Applied Medical Resources Corporation | Natural orifice surgery system |
US9289115B2 (en) | 2010-10-01 | 2016-03-22 | Applied Medical Resources Corporation | Natural orifice surgery system |
KR102641182B1 (en) | 2011-05-10 | 2024-02-28 | 어플라이드 메디컬 리소시스 코포레이션 | Wound retractor |
CN102309786B (en) * | 2011-07-21 | 2012-11-28 | 珠海成富医疗器材有限公司 | System for filling fluid into rectum and reducing temperature of human body |
WO2013106347A1 (en) | 2012-01-10 | 2013-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for the prevention of surgical site infections |
US10327751B2 (en) | 2013-03-20 | 2019-06-25 | Prescient Surgical, Inc. | Methods and apparatus for reducing the risk of surgical site infections |
US9402612B2 (en) | 2013-03-14 | 2016-08-02 | Precient Surgical, Inc. | Methods and devices for the prevention of incisional surgical site infections |
EP2967512B1 (en) | 2013-03-15 | 2019-11-06 | Applied Medical Resources Corporation | Mechanical gel surgical access device |
ES2703184T3 (en) | 2014-07-18 | 2019-03-07 | Applied Med Resources | Method for manufacturing gels that have permanent tack-free coatings |
EP3179934B1 (en) | 2014-08-15 | 2019-03-27 | Applied Medical Resources Corporation | Natural orifice surgery system |
CA2968846A1 (en) | 2014-11-25 | 2016-06-02 | Applied Medical Resources Corporation | Circumferential wound retraction with support and guidance structures |
EP3769704B1 (en) | 2015-09-15 | 2022-11-30 | Applied Medical Resources Corporation | Surgical robotic access system |
US10575840B2 (en) | 2015-10-07 | 2020-03-03 | Applied Medical Resources Corporation | Wound retractor with multi-segment outer ring |
USD796672S1 (en) * | 2015-10-13 | 2017-09-05 | Fortimedix Surgical B.V. | Introducer with trocar |
AU2017324450B2 (en) | 2016-09-12 | 2022-09-29 | Applied Medical Resources Corporation | Surgical robotic access system for irregularly shaped robotic actuators and associated robotic surgical instruments |
CN107320795B (en) * | 2017-08-17 | 2023-06-09 | 山东省肿瘤防治研究院 | Distributed anti-blocking abdominal cavity hot perfusion drainage tube |
WO2019094502A1 (en) | 2017-11-07 | 2019-05-16 | Prescient Surgical, Inc. | Methods and apparatus for prevention of surgical site infection |
CN107736933B (en) * | 2017-11-29 | 2019-12-13 | 陈贵敏 | Abdominal cavity hot perfusion joint control device |
CN109172338B (en) * | 2018-09-13 | 2020-09-08 | 陕西中医药大学附属医院 | Rheumatism immunity branch of academic or vocational study is with traditional chinese medicine fumigation treatment device |
WO2021216885A1 (en) * | 2020-04-22 | 2021-10-28 | Freshwater Holdings Llc | Medical isolation devices and methods |
CN113521495A (en) * | 2021-07-14 | 2021-10-22 | 四川大学华西医院 | Dredging device for abdominal cavity hot perfusion pipeline |
CN114177381B (en) * | 2022-01-10 | 2024-01-26 | 吴菁菁 | Clinical ascites drainage equipment of gastroenterology |
CN115721478B (en) * | 2023-01-10 | 2023-11-14 | 北京安吉贝玛健康科技有限公司 | Abdominal cavity circulation heat perfusion device for tumor treatment |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2403400A (en) | 1941-11-03 | 1946-07-02 | James A Reyniers | Surgical operating device |
NL60818C (en) * | 1945-09-03 | 1900-01-01 | ||
FR2188437A5 (en) | 1972-06-05 | 1974-01-18 | Calhene | |
US3907389A (en) | 1973-12-12 | 1975-09-23 | Marion E Cox | Glove box chamber |
US4275719A (en) * | 1979-03-30 | 1981-06-30 | Nathan Mayer | Apparatus and method for providing an aseptic surgical environment |
US4550713A (en) | 1983-03-10 | 1985-11-05 | Hyman Frederic E Dr | Method and apparatus for opposing deformity, displacement, and expulsion of the ocular tissues during open eye surgery |
DE3689875T2 (en) * | 1985-04-23 | 1994-12-08 | Lone Star Med Prod | ISOLATOR FOR SURGERY. |
HU196265B (en) | 1986-04-11 | 1988-10-28 | Rolitron Mueszaki Fejlesztoe K | Method and apparatus for producing flow of wanted temperature of a physiological solution, as well as temperature control method and a heating device for the previously mentioned method and apparatus |
US4872458A (en) | 1986-09-16 | 1989-10-10 | Olympus Optical Co., Ltd. | Thermotherapy apparatus |
US5003991A (en) | 1987-03-31 | 1991-04-02 | Olympus Optical Co., Ltd. | Hyperthermia apparatus |
US4865049A (en) * | 1988-03-21 | 1989-09-12 | Gatti John E | Smoke eliminating shield for electrocautery surgery |
DE4034705A1 (en) | 1990-10-31 | 1992-05-07 | Martin Neumann | WOUND CLOSURE |
US5178162A (en) * | 1992-04-14 | 1993-01-12 | Bose William J | Splash and spill resistant extremity irrigation and debridement surgical drape |
US5336171A (en) | 1993-12-09 | 1994-08-09 | Sugarbaker Paul H | Abdomino-pelvic lavage apparatus and method |
US5620407A (en) * | 1995-06-12 | 1997-04-15 | Chang; Elise S. | Active control containment system for limiting occupational exposure to biohazardous materials |
-
1999
- 1999-11-12 US US09/438,479 patent/US6383162B1/en not_active Expired - Fee Related
-
2000
- 2000-11-09 EP EP00975625A patent/EP1231954A4/en not_active Withdrawn
- 2000-11-09 AU AU13646/01A patent/AU769641B2/en not_active Ceased
- 2000-11-09 CA CA002390476A patent/CA2390476C/en not_active Expired - Fee Related
- 2000-11-09 WO PCT/US2000/030923 patent/WO2001034224A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2001034224A1 (en) | 2001-05-17 |
EP1231954A1 (en) | 2002-08-21 |
US6383162B1 (en) | 2002-05-07 |
AU769641B2 (en) | 2004-01-29 |
AU1364601A (en) | 2001-06-06 |
EP1231954A4 (en) | 2007-04-25 |
CA2390476A1 (en) | 2001-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2390476C (en) | Apparatus and method for abdomino-pelvic chemotherapy perfusion and lavage | |
Stuart et al. | Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C | |
CA2119156C (en) | Surgical isolation apparatus | |
CN100512905C (en) | Fluid delivery systems, devices and methods for delivery of hazardous fluids | |
JP6553784B2 (en) | Gas / fluid separation device | |
US20140228801A1 (en) | Body cavity drainage device and methods for using the same | |
US5336171A (en) | Abdomino-pelvic lavage apparatus and method | |
EP2347777A1 (en) | Bursitis treatment device and method | |
Kapan et al. | Totally laparoscopic pericystectomy in hepatic hydatid disease | |
JP2002500072A (en) | Method and apparatus for disinfecting a subcutaneous implant device | |
DE10297559T5 (en) | Modular thermal treatment systems with disposable disposable catheter assemblies and associated methods | |
Doane | Administering intraperitoneal chemotherapy using a peritoneal port | |
US20190192792A1 (en) | Agitation apparatus | |
CN208405752U (en) | A kind of cancer of pancreas radiotherapy implantation catheter | |
RU2324503C1 (en) | Device for sanation of abdominal cavity in abdominal surgery followed by laparostoma | |
JP2021524333A (en) | Treatment methods and equipment using systems to control the flow of gaseous media | |
McDermott et al. | An isolated limb infusion technique: a guide for the perfusionist | |
CN211535846U (en) | Drainage warming device for abdominal cavity operation chemotherapy | |
CN213723780U (en) | Medical treatment gynaecology and obstetrics ward soaks disinfection machine with bedding | |
JP2005520649A (en) | Intraductal management of breast lesions using therapeutic or diagnostic agents | |
CN213789172U (en) | Operation trousers | |
GB2553460A (en) | Agitation apparatus | |
RU2242170C2 (en) | Method and device for healing generalized abdominal cavity peritonitis | |
CN2834511Y (en) | Fumigation physiotherapy equipment for treating hemorrhoid | |
FORREST et al. | Delineation of the parotid gland by in vivo staining |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |